Gaiane M. Rauch, M.D., Ph.D.

Peer-Reviewed Articles

1. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
2. Paroder V, Fraum TJ, Nougaret S, Petkovska I, Rauch GM, Kaur H. Key clinical trials in rectal cancer shaping the current treatment paradigms: reference guide for radiologists. Abdom Radiol (NY). e-Pub 2023. PMID: 37221342.
3. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: A phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. e-Pub 2023. PMID: 37043123.
4. Phillips CM, Lima EABF, Wu C, Jarrett AM, Zhou Z, Elshafeey N, Ma J, Rauch GM, Yankeelov TE. Assessing the identifiability of model selection frameworks for the prediction of patient outcomes in the clinical breast cancer setting. J Comput Sci. e-Pub 2023.
5. Awiwi MO, Kaur H, Ernst R, Rauch GM, Morani AC, Stanietzky N, Palmquist SM, Salem UI. Restaging MRI of rectal adenocarcinoma after neoadjuvant chemoradiotherapy: Imaging findings and potential pitfalls. Radiographics 43(4):e220135, 2023. PMID: 36927125.
6. El Homsi M, Sheedy SP, Rauch GM, Ganeshan DM, Ernst RD, Golia Pernicka JS. Follow-up imaging of anal cancer after treatment. Abdom Radiol (NY). e-Pub 2023. PMID: 37024606.
7. Heller S, Smith K, Hunt K, Rauch GM, Fowler A. Molecular breast imaging in the screening setting. JBI. e-Pub 2023.
8. Golia Pernicka JS, Rauch GM, Gangai N, Bates DDB, Ernst R, Hope TA, Horvat N, Sheedy SP, Gollub MJ. Imaging of anal squamous cell carcinoma: Survey results and expert opinion from the Rectal and anal cancer disease-focused panel of the Society of Abdominal Radiology. Abdom Radiol (NY). e-Pub 2023. PMID: 36932225.
9. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Assessment of response to neoadjuvant systemic treatment in triple-negative breast cancer using functional tumor volumes from longitudinal dynamic contrast-enhanced MRI. Cancers (Basel) 15(4), 2023. e-Pub 2023. PMID: 36831368.
10. Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer 9(1):2, 2023. e-Pub 2023. PMID: 36627285.
11. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep 13(1):1171, 2023. e-Pub 2023. PMID: 36670144.
12. Musall BC, Adrada BE, Candelaria RP, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Santiago L, Whitman GJ, Moseley TW, Scoggins ME, Mahmoud HS, White JB, Hwang KP, Elshafeey NA, Boge M, Zhang S, Litton JK, Valero V, Tripathy D, Thompson AM, Yam C, Wei P, Moulder SL, Pagel MD, Yang WT, Ma J, Rauch GM. Quantitative apparent diffusion coefficients from peritumoral regions as early predictors of response to neoadjuvant systemic therapy in triple-negative breast cancer. J Magn Reson Imaging 56(6):1901-1909, 2022. e-Pub 2022. PMID: 35499264.
13. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Exceptional Responders Clinical Trials Group. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517-1524, 2022. e-Pub 2022. PMID: 36306810.
14. Maheshwari E, Nougaret S, Stein EB, Rauch GM, Hwang KP, Stafford RJ, Klopp AH, Soliman PT, Maturen KE, Rockall AG, Lee SI, Sadowski EA, Venkatesan AM. Update on MRI in evaluation and treatment of endometrial cancer. Radiographics 42(7):220070, 2022. e-Pub 2022. PMID: 36018785.
15. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Huo L, White JB, Tripathy D, Valero V, Litton JK, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. Cancer Res 82(18):3394-3404, 2022. e-Pub 2022. PMID: 35914239.
16. Lopez BP, Rauch GM, Adrada B, Kappadath SC. Functional tumor diameter measurement with Molecular Breast Imaging: Development and clinical application. Biomed Phys Eng Express 8(5), 2022. e-Pub 2022. PMID: 35917778.
17. Jacobsen MC, Beriwal S, Dyer BA, Klopp AH, Lee SI, McGinnis GJ, Robbins JB, Rauch GM, Sadowski EA, Simiele SJ, Stafford RJ, Taunk NK, Yashar CM, Venkatesan AM. Contemporary image-guided cervical cancer brachytherapy: Consensus imaging recommendations from the Society of Abdominal Radiology and the American Brachytherapy Society  . Brachytherapy 17(4):369-388, 2022. e-Pub 2022. PMID: 35725550.
18. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
19. Candelaria RP, Adrada BE, Lane DL, Rauch GM, Moulder SL, Thompson AM, Bassett RL, Arribas EM, Le-Petross HT, Leung JWT, Spak DA, Ravenberg EE, White JB, Valero V, Yang WT. Midtreatment ultrasound descriptors as qualitative imaging biomarkers of pathologic complete response in patients with triple negative breast cancer. Ultrasound Med Biol 48(6):1010-1018, 2022. e-Pub 2022. PMID: 35300879.
20. Hruska CB, Corion C, de Geus-Oei LF, Adrada BE, Fowler AM, Hunt KN, Kappadath SC, Pilkington P, Arias-Bouda LMP, Rauch GM. SNMMI Procedure Standard / EANM Practice Guideline for Molecular Breast Imaging with Dedicated Gamma-Cameras. JNMT 50(2):103-110, 2022.
21. Shinagare AB, Sadowski EA, Park H, Brook OR, Forstner R, Wallace SK, Horowitz JM, Horowitz N, Javitt M, Jha P, Kido A, Lakhman Y, Lee SI, Manganaro L, Maturen KE, Nougaret S, Poder L, Rauch GM, Reinhold C, Sala E, Thomassin-Naggara I, Vargas HA, Venkatesan A, Nikolic O, Rockall AG. Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR uterine and ovarian cancer disease-focused panel and the ESUR female pelvic imaging working group. Eur Radiol 32(5):3220-3235, 2022. e-Pub 2021. PMID: 34846566.
22. Adrada BE, Guirguis MS, Hoang T, Spak DA, Rauch GM, Moseley TW. MRI-guided breast biopsy case-based review: Essential techniques and approaches for success with challenging cases. Radiographics 42(2):210126, 2022. e-Pub 2022. PMID: 35119965.
23. Guirguis MS, Adrada BE, Scoggins ME, Moseley TW, Dryden MJ, Le-Petross HC, Rauch GM, Whitman GJ. The challenging image-guided preoperative breast localization: A modality-based approach. AJR Am J Roentgenol 218(3):423-434, 2022. e-Pub 2021. PMID: 34612680.
24. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic impact of high baseline stromal tumor-infiltrating lymphocytes in the absence of pathologic complete response in early-stage triple-negative breast cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
25. Guirguis MS, Checka C, Adrada BE, Whitman GJ, Dryden MJ, Sun J, Ding QQ, Le-Petross H, Rauch GM, Clemens M, Moseley TW. Bracketing with multiple radioactive seeds to achieve negative margins in breast conservation surgery: multiple seeds in breast surgery. Clin Breast Cancer 22(2):e158-e166, 2022. e-Pub 2021. PMID: 34187752.
26. Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 149:110220. e-Pub 2022. PMID: 35193025.
27. Candelaria RP, Spak DA, Rauch GM, Huo L, Bassett RL, Santiago L, Scoggins ME, Guirguis MS, Patel MM, Whitman GJ, Moulder SL, Thompson AM, Ravenberg EE, White JB, Abuhadra NK, Valero V, Litton J, Adrada BE, Yang WT. BI-RADS ultrasound lexicon descriptors and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer. Acad Radiol 29 Suppl 1:S35-S41, 2022. e-Pub 2021. PMID: 34272161.
28. Covington MF, Parent EE, Dibble EH, Rauch GM, Fowler AM. Advances and future directions in Molecular Breast Imaging. J Nucl Med 63(1):17-21, 2022. e-Pub 2021. PMID: 34887334.
29. Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of artificial intelligence to plasma metabolomics profiles to predict response to neoadjuvant chemotherapy in triple-negative breast cancer. Front Artif Intell 5:876100, 2022. e-Pub 2022. PMID: 36034598.
30. Kaur H, Gabriel H, Taggart M, Kang HC, Konishi T, Rauch GM, Krishnan S, Chang G. MRI staging in an evolving management paradigm for rectal cancer, from the AJR Special Series on cancer staging. AJR Am J Roentgenol 217(6):1282-1293, 2021. e-Pub 2021. PMID: 33949877.
31. Expert Panel on GYN and OB Imaging, Kilcoyne A, Gottumukkala RV, Kang SK, Akin EA, Hauck C, Hindman NM, Huang C, Khanna N, Paspulati R, Rauch GM, Said T, Shinagare AB, Stein EB, Venkatesan AM, Maturen KE. ACR Appropriateness Criteria® staging and follow-up of primary vaginal cancer. J Am Coll Radiol 18(11S):S442-S455, 2021. PMID: 34794599.
32. Rauch GM, Kuerer HM, Jochelson MS. To look or not to look? Yes to nodal ultrasound!. J Breast Imaging 3(6):659-665, 2021.
33. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Elshafeey NA, White JB, Musall BC, Miyoshi M, Wang X, Kotrotsou A, Wei P, Hwang KP, Ma J, Pagel MD. Assessment of early response to neoadjuvant systemic therapy in triple-negative breast cancer using amide proton transfer-weighted chemical exchange saturation transfer MRI: A pilot study. Radiol Imaging Cancer 3(5):e200155, 2021. PMID: 34477453.
34. Adrada BE, Candelaria R, Moulder S, Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L, Scoggins ME, Moseley TW, White JB, Ravenberg EE, Yang WT, Rauch GM. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer 127(16):2880-2887, 2021. e-Pub 2021. PMID: 33878210.
35. Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Le-Petross H, Arribas E, Lane DL, Spak DA, Leung JWT, Hwang KP, Son JB, Elshafeey NA, Mahmoud HS, Wei P, Sun J, Zhang S, White JB, Ravenberg EE, Litton JK, Damodaran S, Thompson AM, Moulder SL, Yang WT, Pagel MD, Rauch GM, Ma J. Functional tumor volume by fast dynamic contrast-enhanced MRI for predicting neoadjuvant systemic therapy response in triple-negative breast cancer. J Magn Reson Imaging 54(1):251-260, 2021. e-Pub 2021. PMID: 33586845.
36. Yam C, Yen EY, Chang JT, Bassett RL, Al-Atrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder-Thompson S, Mittendorf EA. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clin Cancer Res 27(19):5365-5375. e-Pub 2021. PMID: 34253579.
37. Lopez BP, Guan F, Rauch GM, Kappadath SC. Monte Carlo simulation of pixelated CZT detector with Geant4: Validation of clinical molecular breast imaging system. Phys Med Biol 66(12), 2021. e-Pub 2021. PMID: 34038878.
38. Expert Panel on GYN and OB Imaging, Lakhman Y, Vargas HA, Reinhold C, Akin EA, Bhosale PR, Huang C, Kang SK, Khanna N, Kilcoyne A, Nicola R, Paspulati R, Rauch GM, Shinagare AB, Small W, Glanc P. ACR Appropriateness Criteria® Staging and follow-up of primary vulvar cancer. J Am Coll Radiol 18(11/5S):S442-S455, 2021. PMID: 33958115.
39. Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. e-Pub 2020. PMID: 32984932.
40. Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185(1):1-12, 2021. e-Pub 2020. PMID: 32920733.
41. Pfob A, Sidey-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Golatta M, Rauch GM, Smith BD, Valero V, Han W, MacNeill F, Weber WP, Rauch G, Kuerer HM, Heil J. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. Eur J Cancer 143:134-146, 2021. e-Pub 2020. PMID: 33307491.
42. Adrada BE, Karbasian N, Huang M, Rauch GM, Woodtichartpreecha P, Whitman G. Imaging surveillance of the reconstructed breast in a subset of patients may aid in early detection of breast cancer recurrence. J Clin Imaging Sci 11:58, 2021. e-Pub 2021. PMID: 34877066.
43. Bragg A, Candelaria R, Adrada B, Huang M, Rauch G, Santiago L, Scoggins M, Whitman G. Imaging of noncalcified ductal carcinoma in situ. J Clin Imaging Sci 11:34, 2021. e-Pub 2021. PMID: 34221643.
44. Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, Cho N, Teoh V, Rauch GM, Smith BD, Valero V, Mohammed K, Han W, MacNeill F, Kuerer HM. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg 155(12):e204103. e-Pub 2020. PMID: 33026457.
45. Adrada BE, Moseley T, Kappadath SC, Whitman GJ, Rauch GM. Molecular breast imaging-guided percutaneous biopsy of breast lesions: a new frontier on breast intervention. J Breast Imaging 2(5):484-491, 2020. e-Pub 2020. PMID: 33015619.
46. Ning MS, Venkatesan AM, Stafford RJ, Bui TP, Carlson R, Bailard NS, Vedam S, Davis R, Olivieri ND, Guzman AB, Incalcaterra JR, McKelvey FA, Thaker NG, Rauch GM, Tang C, Frank SJ, Joyner MM, Lin LL, Jhingran A, Eifel PJ, Klopp AH. Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: methods, process workflow, and value-based analysis. Brachytherapy 19(4):427-437, 2020. e-Pub 2019. PMID: 31786169.
47. Candelaria RP, Adrada BE, Hess K, Santiago L, Lane DL, Thompson AM, Moulder SL, Huang ML, Arribas EM, Rauch GM, Leung JWT, Symmans WF, Valero V, Ravenberg EE, White JB, Yang WT. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol 130:109170. e-Pub 2020. PMID: 32777736.
48. Rauch G, Ueno N, Le-Petross HC. Inflammatory breast cancer. RSNA Case Collection. e-Pub 2020.
49. Kaur H, Ernst RD, Rauch GM, Harisinghani M. Nodal drainage pathways in primary rectal cancer: anatomy of regional and distant nodal spread. Abdom Radiol (NY) 44(11):3527-3535, 2019. e-Pub 2019. PMID: 31628513.
50. Ganeshan D, Nougaret S, Korngold E, Rauch GM, Moreno CC. Locally recurrent rectal cancer: what the radiologist should know. Abdom Radiol (NY) 44(11):3709-3725, 2019. e-Pub 2019. PMID: 30953096.
51. Golia Pernicka JS, Sheedy SP, Ernst RD, Minsky BD, Ganeshan D, Rauch GM. MR staging of anal cancer: What the radiologist needs to know. Abdom Radiol (NY) 44(11):3726-3739, 2019. e-Pub 2019. PMID: 31041496.
52. Hope TA, Gollub MJ, Arya S, Bates DDB, Ganeshan D, Harisinghani M, Jhaveri KS, Kassam Z, Kim DH, Korngold E, Lalwani N, Moreno CC, Nougaret S, Paroder V, Paspulati RM, Golia Pernicka JS, Petkovska I, Pickhardt PJ, Rauch GM, Rosenthal MH, Sheedy SP, Horvat N. Rectal cancer lexicon: consensus statement from the Society of Abdominal Radiology rectal & anal cancer disease-focused panel. Abdom Radiol (NY) 44(11):3508-3517, 2019. e-Pub 2019. PMID: 31388697.
53. Sun S, van la Parra RFD, Rauch GM, Checka C, Tadros AB, Lucci A, Teshome M, Black D, Hwang RF, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy. Ann Surg Oncol 26(10):3071-3079, 2019. e-Pub 2019. PMID: 31342361.
54. Venkatesan AM, Menias CO, Jones KM, Rauch GM, Stafford RJ, Klopp AH. MRI for radiation therapy planning in human papillomavirus-associated gynecologic cancers. Radiographics 39(5):1476-1500, 2019. e-Pub 2019. PMID: 31498740.
55. Park KU, Kuerer HM, Rauch GM, Leung JWT, Sahin AA, Wei W, Li Y, Black DM. Digital breast tomosynthesis for intraoperative margin assessment during breast-conserving surgery. Ann Surg Oncol 26(6):1720-1728, 2019. e-Pub 2019. PMID: 30877499.
56. Adrada B, Rauch GM. Molecular breast imaging in evaluating breast cancer extent of disease. JBI 1(2):155-156, 2019. e-Pub 2019.
57. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol 114:167-174, 2019. e-Pub 2019. PMID: 31005169.
58. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal carcinoma in situ and margins <2mm: contemporary outcomes with breast conservation. Ann Surg 269(1):150-157, 2019. e-Pub 2017. PMID: 28742682.
59. Tayyab SJ, Adrada BE, Rauch GM, Yang WT. A pictorial review: multimodality imaging of benign and suspicious features of fat necrosis in the breast. Br J Radiol 91(1092):20180213, 2018. e-Pub 2018. PMID: 29987981.
60. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
61. Speer ME, Huang ML, Dogan BE, Adrada BE, Candelaria RP, Hess KR, Hansakul P, Yang WT, Rauch GM. High risk breast lesions identified on MRI-guided vacuum-assisted needle biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol 91(1090):20180300, 2018. e-Pub 2018. PMID: 29947265.
62. Rauch GM, Kuerer HM, Adrada B, Santiago L, Moseley T, Candelaria RP, Arribas E, Sun J, Leung JWT, Krishnamurthy S, Yang WT. Biopsy feasibility trial for breast cancer pathologic complete response detection after neoadjuvant chemotherapy: imaging assessment and correlation endpoints. Ann Surg Oncol 25(7):1953-1960, 2018. e-Pub 2018. PMID: 29667115.
63. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg 267(5):946-951, 2018. e-Pub 2017. PMID: 28549010.
64. van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg 105(5):535-543, 2018. e-Pub 2018. PMID: 29465744.
65. Adrada BE, Candelaria R, Rauch GM. MRI for the staging and evaluation of response to therapy in breast cancer. Top Magn Reson Imaging 26(5):211-218, 2017. PMID: 28961570.
66. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152(7):665-670, 2017. e-Pub 2017. PMID: 28423171.
67. Huang ML, Speer M, Dogan BE, Rauch GM, Candelaria RP, Adrada BE, Hess KR, Yang WT. Imaging-concordant benign MRI-guided vacuum-assisted breast biopsy may not warrant MRI follow-up. AJR Am J Roentgenol 208(4):1-7, 2017. e-Pub 2017. PMID: 28140609.
68. Ho JC, Allen PK, Bhosale PR, Rauch GM, Fuller CD, Mohamed AS, Frumovitz M, Jhingran A, Klopp AH. Diffusion-weighted magnetic resonance imaging as a predictor of outcome in cervical cancer after chemoradiation. Int J Radiat Oncol Biol Phys 97(3):546-553, 2017. e-Pub 2016. PMID: 28011045.
69. Rauch GM, Adrada BE, Kuerer HM, van la Parra RF, Leung JW, Yang WT. Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer. AJR Am J Roentgenol 208(2):1-10, 2017. e-Pub 2016. PMID: 27809573.
70. Parikh AM, Coletta AM, Yu ZH, Rauch GM, Cheung JP, Court LE, Klopp AH. Development and validation of a rapid and robust method to determine visceral adipose tissue volume using computed tomography images. PLoS One 12(8):e0183515, 2017. e-Pub 2017. PMID: 28859115.
71. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS margins and breast conservation: MD Anderson Cancer Center multidisciplinary practice guidelines and outcomes. J Cancer 8(14):2653-2662, 2017. e-Pub 2017. PMID: 28928852.
72. Swanick CW, Castle KO, Vedam S, Munsell MF, Turner LM, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Comparison of computed tomography- and magnetic resonance imaging-based clinical target volume contours at brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 96(4):793-800, 2016. e-Pub 2016. PMID: 27788952.
73. Rauch GM, Hobbs BP, Kuerer HM, Scoggins ME, Benveniste AP, Park YM, Caudle AS, Fox PS, Smith BD, Adrada BE, Krishnamurthy S, Yang WT. Microcalcifications in 1657 patients with pure ductal carcinoma in situ of the breast: correlation with clinical, histopathologic, biologic features, and local recurrence. Ann Surg Oncol 23(2):482-9, 2016. e-Pub 2015. PMID: 26416712.
74. Swanick CW, Castle KO, Rechner LA, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer. Brachytherapy 14(3):385-9, 2015. e-Pub 2015. PMID: 25620163.
75. Scoggins ME, Fox PS, Kuerer HM, Rauch GM, Benveniste AP, Park YM, Lari SA, Krishnamurthy S, Yang WT. Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients. AJR Am J Roentgenol 204(4):878-888, 2015. PMID: 25794082.
76. Adrada BE, Miranda RN, Clemens MW, Rauch GM, Arribas E, Fanale M, Haideri N, Mustafa E, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: analysis of imaging studies in 44 patients reveals need for systematic assessment of mass versus no mass to improve diagnostic accuracy. Plast Reconstr Surg 134(4S-1):95-96, 2014. PMID: 25254804.
77. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat 147(1):1-14, 2014. e-Pub 2014. PMID: 25073777.
78. Rauch GM, Kaur H, Choi H, Ernst RD, Klopp AH, Boonsirikamchai P, Westin SN, Marcal LP. Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer. Radiographics 34(4):1082-98, 2014. PMID: 25019443.
79. Verma J, Sulman EP, Jhingran A, Tucker SL, Rauch GM, Eifel PJ, Klopp AH. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys 88(2):357-62, 2014. PMID: 24411609.
80. Rauch GM, Kuerer HM, Scoggins ME, Fox PS, Benveniste AP, Park YM, Lari SA, Hobbs BP, Adrada BE, Krishnamurthy S, Yang WT. Clinicopathologic, mammographic, and sonographic features in 1187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat 139(3):639-647, 2013. e-Pub 2013. PMID: 23774990.
81. Kaur H, Choi H, You YN, Rauch GM, Jensen CT, Hou P, Chang GJ, Skibber JM, Ernst RD. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics 32(2):389-409, 2012. PMID: 22411939.
82. Rauch GM, Dogan BE, Smith TB, Liu P, Yang WT. Outcome analysis of 9-gauge MRI-guided vacuum-assisted core needle breast biopsies. AJR Am J Roentgenol 198(2):292-9, 2012. PMID: 22268171.
83. Meyer JA, Li Y-S, Rauch GM, Haque A. Risk factors for accelerated cerebral degenerative changes and cognitive decline. Research and Practice in Alzheimer's Disease and Other Dementias 5:27-30, 2001.
84. Meyer JS, Thornby J, Li Y-S, Rauch GM. Migraine cluster and chronic daily headaches often accompanied by cognitive decline. John Hopkins University Advanced Studies in Medicine 1:97-100, 2001.
85. Meyer JS, Thornby J, Crawford K, Rauch GM. Reversible cognitive decline accompanies migraine and cluster headaches. Headache 40(8):638-646, 2000. PMID: 10971660.
86. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Ann N Y Acad Sci 903:411-23, 2000. PMID: 10818532.
87. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment and dementia. Neurobiol Aging 21(2):161-169, 2000.
88. Meyer JS, Rauch GM. Why emergency XeCT-CBF should become routine in acute ischemic stroke before thrombolytic therapy. Keio J Med 49 Suppl 1:A25-8, 2000. PMID: 10750330.
89. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K. XE-CT CBF changes during normative aging, cognitive decline and dementia. Keio J Med 49 Suppl 1:A95-7, 2000. PMID: 10750350.
90. Meyer JS, Rauch GM, Crawford K, Rauch RA, Konno S, Akiyama H, Terayama Y, Haque A. Risk factors accelerating cerebral degenerative changes, cognitive decline and dementia. Int J Geriatr Psychiatry 14(12):1050-61, 1999. PMID: 10607973.
91. Mortel KF, Meyer JS, Rauch GM, Konno S, Haque A, Rauch RA. Factors influencing survival among patients with vascular dementia and Alzheimer's disease. J Stroke Cerebrovasc Dis 8(2):57-65, 1999. PMID: 17895141.
92. Konno S, Meyer JS, Margishvili GM, Rauch RA, Haque A. Transformed migraine is a cause of chronic daily headaches. Headache 39(2):95-100, 1999. PMID: 15613201.
93. Meyer JS, Konno S, Margishvili GM, Terayama Y. Vasodilator responses to acetazolamide tested in subtypes of vascular dementia. J Stroke Cerebrovasc Dis 7(5):323-329, 1998. PMID: 17895108.
94. Meyer JS, Terayama Y, Konno S, Margishvili GM, Akiyama H, Rauch RA, Mortel KF, Wills PM. Age-related cerebrovascular disease alters the symptomatic course of migraine. Cephalalgia 18:202-208, 1998. PMID: 9642495.
95. Meyer JS, Terayama Y, Konno S, Akiyama H, Margishvili GM, Motel KF. Risk factors for cerebral degenerative changes and dementia. Eur Neurol 39S:7-16, 1998. PMID: 10607973.
96. Konno S, Meyer JS, Terayama Y, Margishvili GM, Mortel KF. Classification, diagnosis and treatment of vascular dementia. Drugs Aging 11:361-373, 1997. PMID: 9359023.
97. Meyer JS, Akiyama H, Konno S, Mortel KF, Margishvili GM. Human aging: risk factors for cerebral atrophy. Ann N Y Acad Sci 826:483-489, 1997. PMID: 9329729.
98. Amcheslavski VG, Demchuk ML, Madorski SV, Toma GI, Margishvili GM, Fokin SV, Savin IA. The use of the preparation of Nimotop in neurosurgical patients. Zh Vopr Neirkhir Im N N Burdenko 3:41-43, 1997. PMID: 9424955.
99. Grindel OM, Koptelov YM, Masherov YL, Voronina IA, Margishvili GM. EEG pathological zone localization in patients with brain tumors by BRAINLOC method. Zhurnal Physiologia cheloveka (Journal of Human Physiology) 23:36-45, 1997.
100. Boldyreva GN, Bragina NN, Margishvili GM, Masherov EL. Effect of a stationary focus of excitation in the limbic structures on spatial-temporal organization of the human EEG. Fiziol Cheloveka 21:18-28, 1995. PMID: http://www.ergopoint.com/mdanderson/login.do;jsessionid=B11A73481A50C7046A2AF3AEC940661F.
101. Livshits AV, Sokolova AA, Margishvili GM. The dynamic changes in the somatosensory evoked potentials in injury of the spinal and spinal cord trauma after meningomyeloradiculolysis. Zh Vopr Neirokhir Im N N Burdenko 1:26-30, 1995. PMID: 7762313.
102. Livshits AV, Sokolova AA, Margishvili GM. Dynamics of somatosensory evoked potentials in patients with spinal tumors. Zhurnal Voprosi Neirochirurgii imeni (Journal Questions of Neurosurgery) 4-5:19-21, 1992.
103. Livshits AV, Sokolova AA, Margishvili MG. [The dynamics of somatosensory evoked potentials in patients with a spinal cord tumor]. Zh Vopr Neirokhir Im N N Burdenko(4-5):19-21, 1992. PMID: 1334307.
104. Kuerer HM, Gibbons C, Rauch GM, Smith B, Valero V, MacNeill F, Weber W, Rauch G, Heil J, Golatta M, Kolbel V. De-escalation of surgical therapy: What does the data support?. EJC.
105. Homsi ME, Sheedy SP, Rauch GM, Ganeshan DM, Ernst RD, Pernicka JSG. Restaging of anal cancer: what radiologists need to know. Abdom Radiol.
106. Adrada BE, Moseley T, Kapoor MM, Scoggins ME, Patel MM, Perez F, Nia ES, Khazai L, Arribas E, Rauch GM, Guirguis MS. The many faces of triple negative breast cancer. Radiographics.
107. Hwang KP, Kotrotsou A, Chen H, Son JB, Panthi B, Boge M, Mohamed RM, Musall B, Zhang S, Adrada BE, Candelaria RP, White JB, Ravenberg E, Tripathy D, Yam C, Litton J, Huo L, Wei P, Thompson A, Pagel MD, Ma J, Yang W, Rauch GM. A radiomics model based on Synthetic MR acquisition for predicting neoadjuvant systemic treatment response in triple-negative breast cancer. Radiol Imaging Cancer.
108. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JR, Seth S, Lim B, Thompson AM, Mittendorf E, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim NK, Routbort MJ, Sahin AA, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S. PTEN in triple negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol.
109. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson A, Mittendorf EA, Adrada B, Damodaran S, Virani K, White, Ravenburg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmons WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive role of baseline stromal tumor-infiltrating lymphocytes and Ki-67 for pathologic complete response in an early-stage triple-negative breast cancer prospective trial. Cancers.
110. Adrada BE, Moseley M, Kapoor MM, Scoggins ME, Patel MM, Perez F, Nia ES, Khazai L, Arribas E, Rauch GM. Guirguis MS, Menias C, Hammer MM, Heller S. Triple-negative breast cancer: a review of histopathology, genomics, and treatment. RadioGraphics.
111. Patel MM, Rauch GM, Adrada BE. Molecular breast imaging and positron emission mammography. PET Clinics.
112. Yankeelov TE, Hormuth II DA, Lima EABF, Lorenzo G, Wu C, Okereke L, Chung C, Rauch GM. Venkatesan. A practical computational framework for n = 1 clinical trials. Clin Cancer Res.
113. Shinagare AB, Burk KS, Kilcoyne A, Akin EA, Chuang L, Hindman NM, Huang C, Rauch GM, Small W. Stein EN. Venkatesan AM, Kang SK. Pretreatment evaluation and follow-up of invasive cancer of the cervix. ACR.

Invited Articles

1. Johnson HM, Valero V, Yang WT, Smith BD, Krishnamurthy S, Shen Y, Lin H, Lucci A, Rauch GM, Kuerer HM. Eliminating breast surgery for invasive cancer with exceptional response to neoadjuvant systemic therapy: Prospective multicenter clinical trial planned initial feasibility endpoint. J Am Coll Surg. e-Pub 2023. PMID: 36856291.
2. Rauch GM, Adrada BE. Comparison of breast MR imaging with molecular breast imaging in breast cancer screening, diagnosis, staging, and treatment response evaluation. Magn Reson Imaging Clin N Am 26(2):273-280, 2018. PMID: 29622132.
3. Adrada BE, Moseley T, Rauch GM. Molecular breast imaging: role as a screening modality. Curr Breast Cancer Rep 8(4):230-235, 2016. e-Pub 2016.

Manuals, Teaching Aids, Other Teaching Publications

1. Sivucha TA, Kochetova AP, Demin VA, Kossichkin MM, Gilinskaia MI, Rauch GM, Olesik I, Liaschevko VI, Volkov AV. Medical and social rehabilitation of the disabled with benign spinal cord tumors: Moscow, 1992.
2. Sivucha TA, Grinchuk VI, Kossichkin MM, Demin VA, Gilinskaia MI, Gendlina IS, Manukian EA, Oleski I, Rauch GM, Smanov KD, Prianikov IV, Malkumiantz TA, Vershinina AB, Polunina LV, Shpirt EI, Drobashenko TG, Petrova OP. Medical and social rehabilitation of the disabled with compromised cerebral venous circulation: Moscow, 1991.

Other Articles

1. Meyer JS, Margishvili GM, Rauch RA, Haque A Late-life migrainous accompaniments. Neurobase, 1998.
2. Meyer JS, Margishvili GM, Rauch RA, Haque A Migrainous infarction. Neurobase, 1998.
3. Meyer JS, Margishvili GM, Konno S Headache associated with metabolic disorders. Neurobase, 1998.
4. Meyer JS, Margishvili GM, Terayama Y, Konno S Headache associated with arterial hypertension. Neurobase, 1997.

Editorials

1. Pfob A, Sidney-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Golatta M, Rauch GM, Smith BD, Valero V, Han W, MacNeill F, Weber WP, Rauch G, Kuerer HM, Heil J. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment. Eur J Cancer 143:178-179, 2021.
2. Rauch GM. ASO Author Reflections: Elimination of breast cancer surgery in complete responders after neoadjuvant chemotherapy: imaging perspective. Ann Surg Oncol 25(Suppl 3):628-629, 2018. PMID: 30244417.
3. Meyer JS, Rauch GM. Gender differences in cerebral perfusion. J Neurol Sci 162(2):113, 1999.

Abstracts

1. Mohamed RM, Panthi B, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, Hwang KP, Le-Petross HT, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Chen H, Sun J, Wei P, Litton JK, Valero V, Yam C, Pagel M, Ma J, Rauch GM. A pre-operative dynamic contrast enhanced MRI-based radiomics models as predictors of treatment response after neoadjuvant systemic therapy in triple negative breast cancer patients. San Antonio Breast Cancer Symposium. e-Pub 2022.
2. Mohamed RM, Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Patel MM, Elshafeey NA, Pashapoor S, Zhou Z, Son JB, Hwang KP, Le-Petross HC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White JB, Ravenberg EE, Clayborn AR, Pagel MD, Chen H, Sun J, Wei P, Thompson A, Moulder S, Korkut A, Huo L, Hunt K, Litton J, Valero V, Tripathy D, Yam C, Ma J, Rauch GM. Multi-Parametric MRI-based radiomics models from tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant systemic therapy in triple negative breast cancer patients. San Antonio Breast Cancer Symposium. e-Pub 2022.
3. Panthi B, Mohamed RM, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Patel MM, Elshafeey NA, Pashapoor S, Zhou Z, Son JB, Hwang KP, Le-Petross HC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White JB, Ravenberg EE, Clayborn AR, Pagel MD, Chen H, Sun J, Wei P, Thompson A, Moulder S, Korkut A, Huo L, Hunt K, Litton J, Valero V, Tripathy D, Yam C, Ma J, Rauch GM. Longitudinal DCE-MRI radiomic models for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. San Antonio Breast Cancer Symposium. e-Pub 2022.
4. Mohamed RM, Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Patel MM, Elshafeey NA, Pashapoor S, Zhou Z, Son JB, Hwang KP, Le-Petross HC, Leung JWT, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley TW, Perez F, White J, Ravenberg EE, Chen H, Sun J, Wei P, Thompson A, Moulder S, Hung KK, Litton J, Valero V, Tripathy D, Yam C, Pagel MD, Ma J, Rauch GM. Multi-parametric MRI-based radiomics models for early neoadjuvant systemic treatment response prediction in triple negative breast cancer (TNBC). Radiological Society of North America Annual Meeting. e-Pub 2022.
5. Guirguis MS, Adrada BE, Patel MM, Perez F, Candelaria RP, Yang W, Sun J, Mohamed Rm, Boge M, Le-Petross HC, Leung JWT, Whitman GJ, Lane DL, Scoggins ME, Moseley TW, Musall B, White J, Zhou Z, Wei P, Son JB, Hwang KP, Panthi B, Pagel M, Huo L, Hunt K, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch GM. Early prediction of chemoresistance versus excellent response in triple negative breast cancer patients with DCE-MRI. Radiological Society of North America Annual Meeting, 2022.
6. Adrada BE, Guirguis MS, Patel MM, Perez F, Candelaria RP, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HC, Leung JWT, Whitman GJ, Lane DL, Scoggins ME, Moseley T, Musall B, White J, Zhou Z, Wei P, Son JB, Hwang KP, Panthi B, Pagel M, Huo L, Hung K, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch GM. Development of a combined model for early prediction of pathologic complete response (pCR) in triple negative breast cancer (TNBC) undergoing neoadjuvant therapy (NAT). Radiological Society of North America Annual Meeting, 2022.
7. Zhou Z, Adrada BE, Candelaria RP, Mohamed Rm, Pashapoor S, Panthi B, Son JB, Xu Z, Hwang KP, Guirguis MS, Yang W, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Moseley T, Scoggins ME, Patel MM, Perez F, White J, Litton J, Valero V, Tripathy D, Yam C, Pagel MD, Ma J, Rauch GM. Deep learning using pre-treatment MRIs and clinical information for prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer. Radiological Society of North America Annual Meeting, 2022.
8. Guirguis MS, Adrada B, Patel M, Perez F, Candelaria R, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HTC, Leung J, Whitman GJ, Lane DL, Scoggins ME, Moseley T, White J, Wei P, Son JB, Hwang K-P, Panthi B, Pagel M, Hunt KK, Thompson AM, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer. San Antonio Breast Cancer Symposium. e-Pub 2022.
9. Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser D, Buzdar A, Candelaria R, Chen J, Clayborn A, Damodaran S, Ding Q, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NK, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleem S, Teshome M, Valero V, White J, Williams m, Woodward WA, Yajima C, Ueno NT, Chen K, Rauch G, Huo L, Tripathy D. Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer. San Antonio Breast Cancer Symposium. e-Pub 2022.
10. Patel MM, Adrada BE, Lopez B, Candelaria RP, Sun J, Boge M, Mohamed RM, Elshafeey N, Whitman G, LePetross HT, Santiago L, Scoggins ME, Lane D, Moseley T, Zylberman G, Saddler J, Leung JWT, Yang WT, Valero V, Kappadath SC, Rauch GM. Quantitative molecular breast imaging for early prediction of neoadjuvant systemic therapy response in locally advanced breast cancer patients. Cancer Res 82(4 Suppl), 2022.
11. Wu, C, Jarrett AM, Zhou Z, Elshafeey NA, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Moulder S, Yam C, Son JB, Ma J, Rauch GM, Yankeelov T. Forecasting treatment response to neoadjuvant systemic therapy in triple negative breast cancer viamathematical modeling and quantitative MRI. Cancer Res 82(4 Suppl), 2022.
12. Rauch GM, Candelaria RP, Guirguis MS, Boge M, Mohamed RMM, Elshafeey N, Sun J, Whitman GJ, Leung J, Le-Petross HC, Santiago L, Lane D, Scoggins M, Spak D, Patel MM, Perez F, White JB, Ravenberg E, Peng W, Tripathy D, Valero V, Litton J, Huo L, Yam C, Thompson A, Ma J, Moulder SL, Yang W, Adrada BE. Integrated model for early prediction of neoadjuvant systemic therapy response in Triple Negative Breast Cancer. Cancer Res 82(4 Suppl), 2022. e-Pub 2021.
13. Elshafeey N, Hwang KP, Adrada BE, Candelaria RP, Boge M, Mahmoud RM, Chen H, Sun J, Yang W, Kotrotsou A, Musall BC, Son JB, Whitman GJ, Leung J, Le-Petross H, Santiago L, Lane DL, Scoggins ME, Spak DA, Guirguis MS, Patel MM, Perez F, Abdelhafez AH, White JB, Hu L, Ravenberg E, Peng W, Thompson A, Damodaran S, Tripathy D, Moulder SL, Yam C, Pagel MD, Ma J, Rauch GM. Radiomics model based on Magnetic Resonance Image Compilation (MagIC) as early predictor of pathologic complete response to neoadjuvant systemic therapy in triple-negative breast cancer. Cancer Res 82(4 Suppl), 2022.
14. Guirguis MS, Adrada BE, Candelaria RP, Sun J, Whitman GJ, Yang WT, Boge M, Mohamed RM, Elshafeey NA, Lane DL, Le-Petross H, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel M, Perez F, Wei P, Tripathy D, White J, Ravenberg E, Huo L, Litton J, Arun B, Valero V, Thompson A, Moulder S, Yam C, Rauch GM. Prediction of response to neoadjuvant systemic therapy in triple negative breast cancer using baseline tumor MRI characteristics and imaging patterns of response. Cancer Res 82(4 Suppl), 2022. e-Pub 2021.
15. Wu C, Jarrett A, Zhou Z, Elshafeey NA, Ma J, Rauch GM, Yankeelov T. Forecasting treatment response to neoadjuvant therapy in triple-negative breast cancer via an image-guided digital twin. Cancer Res 82(Issue 4 Suppl), 2022.
16. Zhou Z, Elshafeey NA, Rauch DE, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, White J, Litton J, Valero V, Tripathy D, Yam C, Son JB, Pagel MD, Rauch GM, Ma J. Prediction of pathological complete response to neoadjuvant systemic therapy of triple negative breast cancers via deep learning (130/250 characters). Radiological Society of North America Annual Meeting, 2021.
17. Candelaria RP, Bassett R, Boge M, Patel M, Lane DL, Adrada BE, Guirguis MS, Le-Petross H, Leung JW, Perez F, Santiago L, Scoggins ME, Spak DA, Whitman GJ, Rauch GM, Yang WT. Immunogenic response and abnormal axillary node morphology in triple negative breast cancer (TNBC) patients. Radiological Society of North America Annual Meeting, 2021.
18. Guirguis MS, Adrada BE, Candelaria RP, Elshafeey NA, Sun J, Yang W, Boge M, Mohamed RM, Le-Petross HC, Whitman GJ, Lane DL, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Wei P, Hash S, Willis B, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Yam C, Moulder S, Rauch GM. Prediction of pathologic complete response in triple negative breast cancer using baseline tumor MRI characteristics and patterns of response during neoadjuvant chemotherapy. Radiological Society of North America, 2021.
19. Awiwi MO, Kaur H, Ernst RD, Rauch M, Morani A, Stanietzky N, Palmquist SM, Salem UI. Restaging MRI of rectal adenocarcinoma after chemoradiotherapy, when we are wrong: pearls, pitfalls and tricky cases. Radiological Society of North America, 2021.
20. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Image-informed mathematical modeling to predict patient-specific treatment response to neoadjuvant systemic therapy in triple negative breast cancer. Seventh Computational Approaches for Cancers Workshop, 2021.
21. Lopez BP, Rauch GM, Kappadath SC. Automating tumor functional diameter measurement with molecular breast imaging for treatment response assessment. Med Phys 48(6):E168, 2021.
22. Slavkova KP, DiCarlo JC, Wadhwa V, Ma J, Rauch GM, Zhou Z, Yankeelov TE. Implementing ConvDecoder with physics-based regularization to reconstruct under-sampled variable-flip angle MRI data of the breast. International Society for Magnetic Resonance in Medicine - Virtual, 2021.
23. Zhou Z, Rauch DE, Son JB, Musall BC, Elshafeey NA, White JB, Pagel MD, Moulder S, Ma J, Rauch GM. Early prediction of pathologic complete response to neoadjuvant systemic therapy for triple-negative breast cancer using deep learning. International Society for Magnetic Resonance in Medicine - Virtual, 2021.
24. Yam C, Mittendorf EA, Sun R, Huo L, Damodaran S, Rauch GM, Candelaria RP, Adrada BE, Seth S, Symmans WF, Murthy RK, White JB, Ravenberg E, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Tripathy D, Moulder SL, Litton JK. Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC). J Clin Oncol 39(15 Suppl), 2021.
25. Guirguis MS, Adrada BE, Le-Petross H, Dryden MJ, Rauch GM, Whitman GJ, Moseley T. Preoperative bracketing of multifocal breast carcinoma: a multimodality approach. Society of Breast Imaging Symposium, 2021.
26. Seth S, Rauch GM, Adrada BE, Huo L, Piwnica-Worms H, Lim B, Thompson AM, Mittendorf EA, Litton JK, White JB, Symmans WF, Draetta GF, Futreal A, Chang J, Moulder SL. A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC): Results from the ARTEMIS trial (NCT02276443). Cancer Res 81(4 Suppl), 2021. e-Pub 2020.
27. Rauch GM, Drukker K, Elshafeey N, Mohamed RMM, Boge M, Adrada BE, Candelaria RP, Salama M, Shkatova I, Giger M, Yang WT. Quantitative Dynamic Contrast-Enhanced (DCE) MRI radiomic phenotypes for prediction of nodal and distal metastasis in breast cancer patients. Cancer Res 81(4 Suppl), 2021. e-Pub 2020.
28. Elshafeey N, Adrada BE, Candelaria RP, Abdelhafez AH, Musall BC, Sun J, Boge M, Mohammed RMM, Mahmoud HS, Son JB, Kotrosou A, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, White J, Ravenberg E, Hwang KP, Wei P, Litton JK, Huo L, Tripathy D, Valero V, Thompson AM, Moulder S, Yang WT, Pagel MD, Ma J, Rauch GM. Radiomic phenotypes from Dynamic Contrast-Enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in Triple Negative Breast Cancer (TNBC). Cancer Res 81(4 Suppl), 2021. e-Pub 2020.
29. Rauch GM, Adrada BE, Candelaria RP, Elshafeey N, Abdelhafez AH, Musall BC, Sun J, Boge M, Mohamed RMM, Son JB, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, White JB, Ravenberg E, Hwang KP, Wei P, Huo L, Litton JK, Valero V, Tripathy D, Thompson AM, Pagel MD, Ma J, Yang WT, Moulder S. Volumetric changes on longitudinal Dynamic Contrast Enhanced MR Imaging (DCE-MRI) as an early treatment response predictor to Neoadjuvant Systemic Therapy (NAST) in Triple Negative Breast Cancer (TNBC) patients. Cancer Res 81(4 Suppl), 2021. e-Pub 2020.
30. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Elshafeey NA, White JB, Lane DL, Leung JWT, Scoggins ME, Spak DA, Arribas E, Ravenberg E, Santiago L, Moseley TW, Whitman GJ, Le-Petross H, Musall BC, Miyoshi M, Wang X, Willis B, Hash S, Kotrotsou A, Wei P, Hwang KP, Thompson A, Moulder SL, Candelaria RP, Yang W, Ma J, Pagel MD. Assessment of early response to neoadjuvant systemic therapy (NAST) of triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: a pilot study. Cancer Res 81(4 Suppl), 2021. e-Pub 2020.
31. Pfob A, Sidey-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Holatta M, Rauch GM, Smith BD, Valero V, MacNeill F, Han W, Weber WP, Rauch G, Kuerer H, Heil J. Identify breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment - an international, multicenter analysis. Cancer Res 81(4 Suppl), 2021. e-Pub 2020.
32. Seth S, Rauch GM, Adrada B, Piwnica-Worms H, Hou L, Thompson AM, Symmans WF, Lim B, White J, Draetta GF, Futreal A, Chang J, Moulder S. Biomarkers predicting response todurvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer. Cancer Res 81(4 Suppl), 2021.
33. Seth S, Rauch GM, Adrada B, Piwnica-Worms H, Hou L, Thompson AM, Symmans WF, Lim B, White J, Draetta GF, Futreal A, Chang J, Moulder S. The role of purinergic signaling in the chemotherapy response of triple negative breast cancer. Cancer Res 81(4 Suppl), 2021.
34. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Elshafeey NA, White JB, Lade DL, Leung JWT, Scoggins ME, Spak DA, Arribas E, Ravenberg E, Santiago L, Moseley TW, Whitman GJ, Le-Petross H, Musall BC, Miyoshi M, Wang X, Willis B, Hash S, Kotrotsou A, Wei P, Hwang KP, Thompson A, Moulder SL, Candelaria RP, Yang W, Ma J, Pagel MD. Pulsed electric field exposure (PEFE) applied in breast cancer: A potential normothermic clinical cancer therapy. Cancer Res 81(4 Suppl), 2021.
35. Rauch GM, Adrada BE, Candelaria RP, Elshafeey N, Abedelhafez AH, Musall BC, Sun J, Boge M, Mohamed RMM, Son JB, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, White JB, Ravenberg E, Hwang KP, Wei P, Huo L, Litton JK, Valero V, Tripathy D, Thompson AM, Pagel MD, Ma J, Yang WT, Moulder S. Patient-reported outcomes from the Phase III IMpassion031 trial of neoadjuvant atezolizumab+ chemotherapy in early triple-negative breast cancer. Cancer Res 81(4 Suppl), 2021.
36. Rauch GM, Candelaria RP, Guirguis MS, Sun J, Elshafeey NA, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Musall B, White J, Wei P, Zhou Z, Pagel M, Ma J, Ravenberg E, Thompson A, Huo L, Litton J, Valero V, Tripathy D, Yam C, Moulder S, Adrada BE. A composite model for pathologic complete response (pCR) prediction in Triple Negative Breast Cancer (TNBC). Radiological Society of North America Annual Meeting, 2021.
37. Rauch GM, Guirguis MS, Candelaria RP, Elshafeey NA, Sun J, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Musall B, White J, Zhou Z, Wei P, Pagel M, Ma J, Damodaran S, Huo L, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Yam C, Moulder S, Adrada BE. Early prediction of chemo resistance versus excellent response in triple negative breast cancer patients (TNBC) with DCE-MRI. Radiological Society of North America Annual Meeting, 2021.
38. Jacobsen M, Ning M, Simiele S, Bruno T, Rauch GM, Brock KK, Stafford RJ, Klopp A, Venkatesan AM. Direct MR-guidance of brachytherapy in gynecologic cancers: workflow considerations, technical development, and clinical benefits. Radiological Society of North America Annual Meeting, 2021.
39. Maheshwari E, Berital S, Klopp AH, Lee SI, Maturen K, Nougaret S, Rauch GM, Axhmwlwe KM, Arwin E, Venkatesan AM. Recurrent tumors of the uterine cervix and corpus: multimodality imaging review and implications for clinical management. Radiological Society of North America Annual Meeting, 2021.
40. Maheshwar E, Hwang KP, Klopp AM, Lee SI, Maturen K, Nougaret S, Rauch GM, Soliman PT, Stafford J, Setin E, Venkatesan AM. The 2021 Update on MRI for endometrial cancer: what the radiologist needs to know. Radiological Society of North America Annual Meeting, 2021.
41. Zhou Z, Elshafeey NA, Rauch DE, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Tripathy D, Valero V, Yam C, Moulder S, White JB, Son JB, Pagel MD, GM Rauch, Ma J. Deep learning for early prediction of neoadjuvant chemotherapy response in triple negative breast cancers. San Antonio Breast Cancer Symposium, 2021.
42. Elshafeey N., Adrada B.E., Candelaria R.P., Abdelhafez A.H., Musall B.C., Sun J., Boge M, Mohamed RMM, Mahmoud HS, Son JB, Kotrosou A, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, White JB, Ravenberg E, Hwang KP, Wei P, Litton JK, Huo L, Tripathy D, Valero V, Thompson Am, Moulder S, Yang WT, Pagel MD, Ma J, Rauch GM. Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119. Cancer Res 81(4 Suppl), 2021.
43. Vasaikar S, Seth S, Hollander PD, Rauch G, Adrada B, Candelaria R, Mittendorf E, Thompson A, Litton J, Lim B, Arun B, Ueno N, Valero V, Ibrahim N, Murthy R, Damodaran S, White J, Tripathi D, Piwnica-Worms H, Symmans WF, Chang J, Mani S, Moulder SL. Assessment of mid-neoadjuvant chemotherapy (NACT) biopsies identifies two potential gene signatures that predict for 2 year recurrence free survival (RFS-2) in triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium - Virtual, 2020.
44. Candelaria RP, Adrada BE, Lane DL, Bassett R, Santiago L, Rauch GM, Moseley T, Scoggins M, Thompson A, Ravenberg E, White J, Spak D, Le-Petross HC, Arribas E, Whitman G, Leung JT, Litton J, Mittendorf E, Huo L, Valero V, Moulder S, Yang WT. BI-RADS ultrasound lexicon descriptors and tumor-infiltrating lymphocytes in triple negative breast cancer. Virtual - Radiological Society of North America Annual Meeting, 2020.
45. Musall B, Abdelhafez AH, Adrada BE, Jon J, Candelaria RP, Sun J, Yang WT, Santiago L, Whitman G, Le-Petross HC, Moseley T, Lane D, Leung JT, Scoggins M, Spak D, Arribas E, Mahmoud H, White J, Hwang KP, Elshafeey N, Mohamed R, Boge M, Kotrotsou A, Zhang S, Damodaran S, Litton J, Valero V, Tripathy D, Thompson A, Wei P, Moulder S, Pagel M, Ma J, Rauch GM. Radiomic features of quantitative apparent diffusion coefficient (ADC) maps from peritumoral regions (PTRs) as predictors of early treatment response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC). Virtual - Radiological Society of North America Annual Meeting, 2020.
46. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed R, Yang WT, Elshafeey N, Sun J, Abdelhafez A, Son JB, White J, Moseley T, Whitman G, Le-Petross HC, Santiago L, Lane D, Leung JT, Scoggins M, Spak D, Arribas E, Ravenberg E, Musall B, Miyoshi M, Wang Z, Willis B, Hash S, Kotrotsou A, Wei P, Hwang KP, Litton J, Thompson A, Moulder S, Candelaria R, Ma J, Pagel M. Assessment of early response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: pilot study. Virtual - Radiological Society of North America Annual Meeting, 2020.
47. Elshafeey NA, Adrada BE, Kotrotsou A, Abdelhafez AH, Candelaria RP, Yang WT, Sun J, Mohamed R, Boge M, Mahmoud H, Musall B, Son JB, Tripathy D, Santiago L, Thompson A, Valero V, Whitman G, Litton J, Lim B, Le-Petross HC, Leung JT, Lane D, Arribas E, Spak D, Scoggins M, Moseley T, Ueno N, Zhang S, White J, Moulder S, Hwang KP, Wei P, Pagel M, Ma, Rauch GM. Radiomic phenotypes from ultrafast dynamic contrast enhanced (DCE) MRI for prediction of the treatment response to neoadjuvant systemic therapy (NAST) of triple negative breast cancer (TNBC). Virtual - Radiological Society of North America Annual Meeting, 2020.
48. Rauch GM, Adrada BE, Candelaria RP, Elshafeey NA, Mohamed RM, Boge M, Moseley T, Whitman G, Le-Petross HC, Santiago L, Lane D, Leung JT, Spak D, Valero V, Litton J, Huo L, Tripathy D, Mittendorf E, Thompson A, Arribas E, Scoggins M, Musall B, Kotrotsou A, Sun J, Son JB, White J, Zhang S, Hwang KP, Wei P, Moulder S, Pagel M, Ma J, Yang WT. Longitudinal MR imaging findings in triple negative breast cancer (TNBC) patients undergoing neoadjuvant systemic therapy (NAST) stratified by tumor infiltrating lymphocytes (TIL) levels. Virtual - Radiological Society of North America Annual Meeting, 2020.
49. Zhang S, Rauch GM, Adrada BE, Abdelhafez AH, Son J, Yang WT, Sun J, Boge M, Mohamed R, Elshafeey N, White J, Musall B, Moseley T, Whitman G, Le-Petross HC, Santiago L, Lane D, Leung JT, Scoggins M, Spak D, Arribas E, Ravenberg E, Miyoshi M, Wang X, Kotrotsou A, Wei P, Hwang KP, Litton J, Thompson A, Candelaria RP, Moulder S, Ma J, Pagel M. Comparison of chemical exchange saturation transfer (CEST) MRI acquisition and analysis for early neoadjuvant systemic therapy (NAST) treatment response assessment in triple negative breast cancer (TNBC). Virtual - Radiological Society of North America Annual Meeting, 2020.
50. Kotrotsou A, Elshafeey NA, Adrada BE, Sun J, Candelaria RP, Abdelhafez AH, Yang WT, Mohamed R, Boge M, Willis B, Musall B, Son JB, Zhang S, Thompson A, Tripathy D, Moseley T, Litton J, Whitman G, Le-Petross HC, Valero V, Santiago L, Lane D, Lim B, Leung JT, Scoggins M, Spak D, Arribas E, White J, Ravenberg E, Cardenas-Rodriguez J, Wei P, Moulder S, Rauch GM, Pagel M. Reliability of pharmacokinetic (PK) parameters by DCE-MRI for prediction of neoadjuvant systemic treatment (NAST) response in triple negative breast cancer (TNBC) patients: a comparison of three analysis methods. Virtual - Radiological Society of North America Annual Meeting, 2020.
51. Guirguis M, Adrada B, Le-Petross HC, Dryden M, Rauch G, Moseley T, Whitman G. Challenging cases in breast localization: a multimodality approach. Virtual - Radiological Society of North America Annual Meeting, 2020.
52. Hwang KP, Vikram R, Ernst R, Rauch G, Devine C, Ma J, Kaur H. Quality improvement and troubleshooting in rectal MRI - how we do it. Virtual - Radiological Society of North America Annual Meeting, 2020.
53. Pagel MD, Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RM, Hamed A, Son JB, Sun J, Elshafeey NA, White JB, Musall BC, Miyoshi M, Wang X, Wei P, Hwang KP, Ma J. Assessment of early response to neoadjuvant systemic therapy (NAST) of triple-negative breast cancer (TNBC). Chemical Exchange Saturation Transfer Imaging 2020 Annual Meeting - Virtual, 2020.
54. Zhang S, Abdelhafez AH, Son JB, Musall BC, Miyoshi M, Wang Z, Hwang KP, Rauch GM, Ma J, Pagel MD. Tumor response to neoadjuvant chemotherapy in triple negative breast cancer using CEST MRI. International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
55. Musall BC, Abdelhafez AH, Mahmoud HS, Hwang KP, Son JB, Pagel MD, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Candelaria RP, Helgason T, Ravenberg EE, Litton JK, Moulder SL, Yang WT, Ma J, Rauch GM, Adrada BE. Diffusion fractional anisotropy in peritumoral edema of triple negative breast cancer. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
56. Hwang KP, Wang X, Ernst RD, Palmquist SM, Level M, Rauch GM, Chang GJ, Messick C, Taggart MW, Bayram E, Ma J, Kaur H. Deep learning based image reconstruction for T2-weighted rectal cancer imaging. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
57. Son JB, Hwang KP, Scoggins ME, Basek ED, Rauch GM, Pagel MD, Ma J. Semi-supervised image domain transfer for Dixon water and fat separation. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
58. Zhang S, Abdelhafez AH, Son JB, Musall B, Miyoshi M, Wang X, Hwang KP, Rauch GM, Ma J, Pagel M. Optimized CEST acquisition and analysis for treatment assessment of response to neoadjuvant chemotherapy in triple-negative breast cancer. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020.
59. Tayyab S, Le-Petross H, Adrada BE, Rauch GM, Moseley T, Sun J, Masood AR. Stromal fibrosis on MRI biopsy: a histopathologic correlation and outcome data. European Congress of Radiology, 2020.
60. Jimenez J, Abeer A, Elshafeey N, Yung J, Hazle J, Rauch G. Quantitative MR imaging features associated with pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. American Association of Physicists in Medicine / Canadian Organization of Medical Physicists Annual Meeting, 2020.
61. Moulder S, Bassett RL, White JB, Huo L, Damodaran S, Lim B, Ueno NT, Murthy RK, Arun B, Valero V, Tripathy D, Hortobagyi GN, Litton JK, Thompson AM, Mittendorf EA, Ravenberg E, Santiago L, Adrada BE, Candelaria RP, Rauch GM. Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple negative breast cancer (TNBC). J Clin Oncol 38(15 Suppl). e-Pub 2020.
62. Yam C, Al-Atrash G, Yen EY, Garber H, Philips AV, Huo L, Yang F, Bassett RL, Sun X, Cuentas RP, Symmans WF, Seth S, White JB, Rauch GM, Damodaran S, Litton JK, Mittendorf EA. Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC). J Clin Oncol 38(15 Suppl). e-Pub 2020.
63. Arun B, Zhao L, Bassett RL, Thompson AL, White JB, Layman RM, Barrera Ag, Valero V, Ueno NT, Litton JK, Zhang J, Ravenberg E, Candelaria RP, Rauch GM, Tripathy D, Moulder SL. Germline alterations other than BRCA in triple negative breast cancer (TNBC) patients who underwent neoadjuvant therapy (NAT) on a prospective clinical trial. J Clin Oncol 38(15 Suppl). e-Pub 2020.
64. Abudadra NK, Lim B, Thompson A, Litton J, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun BK, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Moulder S, Huo L, White JB, Ravenberg EE, Sun R. The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumor infiltrating lymphocytes (sTIL). Ann Oncol 31(Suppl 2):S49, 2020.
65. Abuhadra NK, Sun R, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf E, Litton E, Damodaran S, Candelaria RP, Arun BK, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Symmans WF, Moulder S, Huo L, White JB, Ravenberg EE. Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC). J Clin Oncol 38(15 Suppl). e-Pub 2020.
66. Lim B, Seth S, Huo L, Layman R, Valero V, Thompson A, White J, Litton J, Damodaran S, Candelaria R, Arun B, Rauch G, Murthy R, Zhao L, Zhang J, Ding Q, Symmans WF, Ramirez D, Ibrahim N, Thomas P, Moulder S, Ueno NT. Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide. J Clin Oncol 38(15 Suppl). e-Pub 2020.
67. Adrada BE, Abdelhafez AH, Musall BC, Hess KR, Son JB, Pagel MD, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Scoggins ME, Spak DA, Leung JWT, Damodaran S, Lim B, Valero V, White J, Thompson AM, Litton JK, Moulder SL, Ma J, Yang WT, Rauch GM. Quantitative apparent diffusion coefficient (ADC) radiomics of tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients. Cancer Res 80(4 Suppl), 2020. e-Pub 2019.
68. Abuhadra NK, Lim B, Thompson A, Mittendorf E, Hess KR, Litton J, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang W, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder S, Huo L. Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC). Cancer Res 80(4 Suppl S), 2020.
69. Tasoulis K, Kuerer HM, MacNeill F, Han-Byoel L, Yang W, Pope R, Krishnamurthy S, Teoh V, Rauch GM, Smith B, Valero V. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: a multi-institutional pooled analysis. Cancer Res 80(4 Suppl), 2020.
70. Seth S, Huo L, Vasaikar S, Rauch G, Lim B, White J, Adrada B, Piwnica-Worms H, Ueno NT, Thompson AM, Mittendorf E, Tripathy D, Litton JK, Symmans WF, Draetta G, Futreal A, Chang J, Moulder S. Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). Cancer Res 80(4 Suppl), 2020. e-Pub 2019.
71. Damodaran S, Litton JK, Hess KR, Eppig CT, Grzegorzewski KJ, Meric-Bernstam F, Wistuba II, White JB, Rauch GM, Candelaria RP, Adrada BE, Lim B, Moulder SL, Tripathy D. A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations. Cancer Res 80(4 Suppl), 2020. e-Pub 2019.
72. Garber H, Rauch G, Adrada B, Candelaria R, Mittendorff E, Thompson A, Litton J, Damodaran S, Lim B, Arun B, Ueno N, Valero V, Ibrahim N, Murthy R, Tripathy D, Piwnica-Worms H, Symmans F, Huo L, Moulder S. Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS). Cancer Res 80(4 Suppl), 2020.
73. Son JB, Hwang KP, Scoggins ME, Dogan BE, Rauch GM, Pagel MD, MaJ. Water and fat separation with a Dixon Conditional Generative Adversarial Network (DixonCGAN). 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020. e-Pub 2020.
74. Abdelhafez AH, Adrada BE, Musall BC, Ma J, Candelaria RP, Yang WT, Hess KR, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DE, Scoggins ME, Leung JWT, Pagel MD, Hwang KP, Son JB, Litton JK, Damodaran S, Lim B, White J, Mahmoud HS, Valero V, Thompson AM, Moulder SL, Rauch GM. Tumor necrosis at baseline dynamic contrast enhanced (DCE) MRI for prediction of neoadjuvant chemotherapy treatment (NACT) response in triple negative breast cancer (TNBC) patients. Radiological Society of North America Annual Meeting. e-Pub 2019.
75. Musall BC, Ma J, Adrada BE, Abdelhafez AH, Candelaria RP, Yang WT, Hess KR, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Leung JWT, Scoggins ME, Pagel MD, Hwang KP, Bon JB, White JB, Litton JK, Damodaran S, Lim B, Willis BJ, Mahmoud HS, Megahed A, Thompson AM, Moulder SL, Rauch GM. Quantitative tumor volumes by fast dynamic contrast enhanced (DCE) MRI predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC). Radiological Society of North America Annual Meeting. e-Pub 2019.
76. Rauch GM, Abdelhafez AH, Musall BC, Hess KR, Son JB, Pagel MD, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Scoggins M, Spak D, Leung JWT, Damodaran S, Lim B, Valero V, White J, Thompson AM, Litton JK, Huo L, Moulder SL, Ma J, Yang WT, Adrada BE. Radiomics of quantitative apparent diffusion coefficient (ADC) from fibroglandular tissue (FGT) for prediction of tumor infiltrating lymphocytes (TIL) levels and neoadjuvant chemotherapy treatment (NACT) response in triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium. e-Pub 2019.
77. Adrada B, Candelaria R, Hess K, Moulder S, Santiago L, Valero V, Arribas E, Moseley T, Lane D, Scoggins M, Le-Petross HC, Spak DA, Huang ML, Litton J, Thompson A, White J, Whitman G, Leung J, Yang W, Rauch G. Precision imaging: early ultrasound evaluation (US) to identify excellent responders to neoadjuvant. Radiological Society of North America Annual Meeting. e-Pub 2019.
78. Candelaria R, Hess K, Lane D, Santiago L, Moulder S, Yang WT, Thompson A, Rauch G, Huang ML, Arribas EM, Scoggins ME, Moseley TW, Le-Petross HC, Spak DA, Whitman GJ, Leung JW, Valero V, Damodaran S, Litton J, White J, Adrada BE. Predicting pathologic complete response with ultrasound tumor characteristics in triple negative breast cancer patients. Radiological Society of North America Annual Meeting. e-Pub 2019.
79. Guirguis M, Adrada B, Dryden M, Le-Petross HC, Rauch G, Checka C, Whitman G, Moseley T. The feasibility of breast conservation therapy in multifocal/multicentric breast cancer using multiple radioactive seeds: a paradigm shift. Radiological Society of North America Annual Meeting. e-Pub 2019.
80. Kaur H, Chang G, Konishi T, You Y, Rauch GM, Ernst R. Pelvic nodal anatomy and patterns of nodal spread in rectal cancer. Radiological Society of North America Annual Meeting. e-Pub 2019.
81. Moawad A, Fuentes D, Carter B, Garg N, Rauch GM, Vining D, Elsayes K. Artificial intelligence in diagnostic imaging: current applications and future perspective. Radiological Society of North America Annual Meeting. e-Pub 2019.
82. Crespo J, Sahil S, Ravenberg E, Huo L, Hess K, Santiago L, Adrada B, Rauch G, Senthil D, Murthy R, Litton J, Tripathy D, Ueno N, Moulder S, Lim B. Characterization of the LAR-subtype triple-negative breast cancer population. Cancer Res 79(13 Suppl):368-369, 2019.
83. Seth S, Crespo J, Huo L, Thompson A, Mittendorf E, Hess K, Litton J, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang W, Santiago L, Murthy RK, Sahin A, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. J Clin Oncol 37(15, Suppl):595. e-Pub 2019.
84. Guirguis M, Santiago L, Adrada BE, Rauch GM, Arribas E. Beyond invasive ductal carcinoma: A review of unusual breast malignancies. Proceedings of the American Roentgen Ray Society Annual Meeting, 2019.
85. Musall BC, Adrada BE, Abdelhafez AH, Mahmoud HS, Hwang KP, Son JB, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Candelaria RP, Helgason T, Ravenburg E, Litton JK, Moulder SL, Yang WT, Ma J, Pagel MD, Rauch GM. Quantitative ADC measurement of breast cancer with ssEPI and reduced FOV diffusion weighted imaging techniques. Proceedings of the 2019 International Society for Magnetic Resonance in Medicine. e-Pub 2019.
86. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria R, Arun B, Yang YT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating (TIL) receiving neoadjuvant therapy. J Clin Oncol 37(15, Suppl), 2019. e-Pub 2019.
87. Tasoulis MK, Lee HB, MacNeill L, Kuerer HM, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: a multi-institutional pooled analysis. American Society of Clinical Oncology Annual Meeting, 2019.
88. Moulder S, Adrada B, Lim B, Ueno N, Candelaria R, Rauch G, Litton J, Thompson A, Huo L, Hess K. A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST). 16th St. Gallen International Breast Cancer Conference Proceedings 44(Suppl 1):S101 - S102, 2019.
89. Adrada BE, Valero V, Reddy SM, Barcenas CH, Candelaria R, Wei W, Rauch GM. Ultrasound assessment of residual disease after neoadjuvant chemotherapy (NACT) in node positive triple negative breast cancer (TNBC). Cancer Res 79(4 Suppl), 2019.
90. Adrada BE, Candelaria R, Moulder S, Lane D, Santiago L, Arribas E, Hess KR, Valero V, Thompson A, Helgason T, Ravenberg E, Yang W, Rauch GM. Early ultrasound evaluation for prediction of treatment response to neoadjuvant chemotherapy in triple negative breast cancer patients. Cancer Res 79(4 Suppl), 2019.
91. Lucci A, Hall C, Hess K, Ravenberg E, Clayborn A, Mittendorf E, Rauch G, Candelaria R, Moulder S, Thompson A. Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC). Cancer Res 79(4 Suppl), 2019.
92. Seth S, Huo L, Rauch G,R, Gilcrease M, Adrada B, Piwnica-Worms H, Symmans WF, Draetta G, Futreal AP, Moulder S, Chang JT. Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). Cancer Res 79(4 Suppl), 2019.
93. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans F, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. Cancer Res 79(4 Suppl), 2019.
94. Seth S, Huo L, Rauch GM, Adrada BE, Piwnica-Worms H, Thompson A, Mittendorf E, Litton J, Symmans WF, Draetta G, Futreal A, Moulder S, Chang JT. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). J Clin Oncol 37(No. 15 Suppl):586-586, 2019.
95. Sun S, Van laParra R, Rauch GM, Checka C, Adrosa T, Lucci A, Teshome M, Black S, Hwang R, Smith B, Krishnamurthy S, Velero V, Yang W, Kuerer HM. Patient selection for non-operative management of HER2+ invasive breast cancer after neoadjuvant systemic therapy. Ann Surg Oncol 26:19 Suppl 2, 2019.
96. Musall BC, Adrada BE, Abdelhafez AM, Hwang KP, Son JB, Santiago L, Whitman G, Le-Petross H, Moseley T, Candelaria RP, Lim B, Damodaran S, Litton J, Moulder S, Yang WT, Ma J, Pagel MD, Rauch GM. Optimized tumor volumes by dynamic contrast enhanced MR imaging for assessing response to neoadjuvant chemotherapy in triple negative breast cancer. Proceedings of the 2019 International Society for Magnetic Resonance in Medicine, 2019.
97. Hwang KP, Son JB, Banerjee S, Zhang T, Ma J, Rauch GM, Warntjes M. 3D multi-parameter mapping of the breast with Dixon fat-water separation. International Society for Magnetic Resonance in Medicine Annual Meeting. e-Pub 2019.
98. Seth S, Huo L, Gilcrease M, Lau R, Piwnica-Worms H, Adrada B, Rauch G, Draetta G, Futreal A, Symmans WF, Moulder S, Chang J. Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). EJC 103S1:E129. e-Pub 2018.
99. Candelaria R, Adrada BE, Santiago L, Lane DL, Wei W, Huang ML, Arribas EM, Rauch GM, Thompson A, Moulder S. Do triple negative breast cancers have characteristic imaging features according to androgen receptor and vimetin status?. Proceedings of the 104th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2018.
100. Litton, JK, Moulder SL, Hess KR, Damodaran S, Rauch GM, Candelaria R, Adrada BE, Symmans F, Murthy RK, Helgason T, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Mittendorf EA. Neoadjuvant trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC). Ann Oncol 29(Suppl 8). e-Pub 2018.
101. Hall C, Hess K, Ravenberg L, Clayborn A, Rauch G, Candelaria R, Mittendorf EA, Moulder S, Thompson A, Lucci A. Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC). Ann Oncol 29(Suppl 8), 2018.
102. Yam C, Seth S, Hess K, Mittendorf EA, Murthy R, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang M, Arribas E, Lane D, Rauch G, Adrada B, Gilcrease M, Chang J, Moulder S. Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC). Ann Oncol 29(Suppl 8), 2018.
103. Yam C, Hess KR, Litton JK, Yang W, Santiago L, Candelaria RP, Mittendorf E, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Moulder SL. Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST). J Clin Oncol 36(15, Suppl), 2018.
104. Moulder S, Hess K, Candelaria RP, Rauch GM, Santiago L, Adrada BE, Yang WT, Gilcrease MZ, Huo L, Stauder MC, Arun B, Layman RM, Murthy RK, Damodaran S, Ueno NT, Thompson AM, Lim B, Mittendorf EA, Litton JK, Symmans WF. Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). J Clin Oncol 36(15 Suppl):518-518, 2018.
105. Scoggins M, Santiago L, Arribas E, Rauch G, Lane D, Adrada B. A sheep in wolf's clothing: imaging assessment of multiple intraductal breast papillomas. American Roentgen Ray Society Annual Meeting, 2018.
106. Scoggins M, Rauch G, Candelaria R, Arribas E, Santiago L, Adrada B. Axillary lymphadenopathy on screening mammography: a first sign of hidden danger?. American Roentgen Ray Society Annual Meeting, 2018.
107. Yam C, Fornage BD, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno N, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans F, Moulder SL, Yang W. Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer (TNBC). Cancer Res 78(4, Suppl):988, 2018.
108. Rauch GM, Li H, Zhu H, Adrada BE, Santiago L, Candelaria R, Wang H, Leung J, Thompson A, Litton J, Wu Y, Lim B, Moulder S, Mittendorf E, Yang W. Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer. Cancer Res 78(4, Suppl):618, 2018.
109. Rauch GM, Adrada BE, Kappadath C, Candelaria RP, Huang ML, Santiago L, Moseley T, Scoggins ME, Knudtson JD, Lopez BP, Hess KR, Krishnamurthy S, Moulder S, Valero V, Yang W. Quantitative assessment of tumor response to neoadjuvant chemotherapy in women with locoregional invasive breast cancer using Tc99m sestamibi molecular breast imaging - preliminary results. Cancer Res 78(4, Suppl):795, 2018.
110. Rauch GM, Zhu H, Li H, Adrada BE, Santiago L, Candelaria R, Wang H, Leung J, Litton J, Wu Y, Murthy R, Mittendorf E, Yang W. Association of quantitative MRI features with tumor infiltrating lymphocytes and treatment response prediction in HER2 positive subtype of breast cancer. Cancer Res 78(4, Suppl):1181, 2018.
111. Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, Mittendorf EA, Euno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Androgen receptor positivity is associated with nodal disease in triple negative breast cancer. Cancer Res 78(4, Suppl):136, 2018.
112. Echeverria GV, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Rauch GM, Adrada B, Candelaria R, Santiago L, Thompson A, Litton J, Moulder S, Symmans F, Chang JT, Piwnica-Worms H. A molecularly annotated collection of breast cancer patient-derived xenograft models aligned with ongoing clinical trials built from fine needle aspiration samples throughout neoadjuvant treatment. J Cancer Res 78(4, Suppl):817, 2018.
113. Rauch GM, Zhu H, Li H, Adrada BE, Santiago L, Yang WT, Candelaria RP, Leung JW, Elbanan M, Duran AH, Unlu E, Wang M, Moulder S, Wu Y, Mittendorf E, Thompson A. Correlation of MRI texture features with tumor infiltrating lymphocytes and pathologic complete response in HER2 positive and triple negative subtypes of breast cancer. Proceedings of the 104th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2018.
114. Rauch GM, Adrada B, Kappadath SC, Lopez B, Hess K, Moseley T, Scoggins M, Candelaria R, Huang M, Knudtson J, Krishnamurthy S, Moulder S, Valero V, Yang W. Prediction of tumor response to neoadjuvant chemotherapy in breast cancer patients using quantitative 99mTc sestamibi Molecular Breast Imaging - Preliminary results. Proceedings of the 104th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2018.
115. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci Jr A, Caudle AS, DeSnyder SM, Teshome M, Barcenas C, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Imaging and imaging-guided biopsy assessment of pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Society of Surgical Oncology, 2017.
116. Son JB, Rauch GM, Hwang KP, Ma J. An automated single-scan Z-spectrum analysis method for amide proton transfer imaging. 39th Annual International Conference of the IEEE Engineering in Medicine & Biology Society, 2017.
117. Damodaran S, Hess K, Rauch M, Adrada B, Santiago L, Litton J, Mittendorf E, Lim B, Ueno N, Tripathy D, Thompson A, Gilcrease M, Yang W, Piwnica-Worms H, Symmans WF, Moulder SL. NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT). Cancer Res 77(13):Supplement, 2017.
118. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci Jr A, Barcenas CH, Hwang RF, Rauch GM, Santiago L, Strom EA, DeSnyder SM, Yang WT Black DM, Albarracin CT, Mac Gregor MC, Hunt KK, Kuerer HM. Contemporary breast conservation patient outcomes for ductal carcinoma in situ and margins <2mm. J Clin Oncol 35(15, Suppl), 2017.
119. Yam C, Hess KR, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran SK, Helgason T, Huo L, Thompson AM, Gilcrease M, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Moulder SL. A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS). J Clin Oncol 35(15, Suppl), 2017.
120. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A Jr, Caudle AS, DeSnyder SM, Teshome M, Barcenas C, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of patients and rationale for elimination of axillary surgery with documented pathologic complete response in the breast after neoadjuvant chemotherapy. Society of Surgical Oncology, 2017.
121. Helgason T, Moulder S, Thompson A, Symmans WF, Hess K, Yang W, Adrada BE, Rauch GM, Gilcrease M, Mittendorf EA, Tripathy D, Ueno NT. NCT02593175: A phase IIB study of neoadjuvant PaCT regimen (panitumumab in combination with carboplatin and paclitaxel) for anthracycline resistant triple-negative breast cancer (TNBC). Cancer Res 77(4, Suppl), 2017.
122. Moulder S, Helgason T, Hess KR, Symmans WF, Adrada BE, Rauch GM, Thompson A, Clayborn AR, Huo L, Gilcrease M, Tripathy D, Mittendorf EA. Triple-negative first-line study: neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489). Cancer Res 77(4, Suppl), 2017.
123. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS S, DeSnyder SM, Santiago L, Lucci A, Hobbs BP, Gilcrease M, Hwang R, Candelaria RP, Chavez Mac-Gregor M, Arribas E, Moseley T, Teshome M, Miggins MV, Smith BD, Valero V, Hunt KK, Yang WT. Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic chemotherapy. Cancer Res 77(4, Suppl), 2017. e-Pub 2016.
124. Echeverria GV, Chang JT, Tu Y, McCoy A, Lau R, Redwood A, Kaffiabasabadi S, Rauch GM, Adrada BE, Jennifer L, Moulder SL, Symmans WF, Piwnica-Worms H. An annotated collection of pre- and post-therapy breast cancer patient-derived xenoggraft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment. Cancer Res 77(4), 2017.
125. Lim B, Helgason T, Hess KR, Piwnica-Worms H, Yang W, Adrada BE, Rauch GM, Gilcrease M, Symmans FW, Huo L, Mittendorf EA, Thompson A, Stacy MTL, Debu T, Ueno NT. Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC). Cancer Res 77(4, Suppl), 2017.
126. Moseley TW, Adrada BE, Rauch GM. Molecular breast imaging. Cancer Study and Therapy Conference, 2017. e-Pub 2017.
127. Arribas E, Huang M, Adrada BE, Rauch GM, Santiago L. The atypical malignant axillary lymph node in breast cancer patients. AJR Am J Roentgenol, 2017.
128. Lopez B, Rauch M, Adrada B, Backe S, Hess K, Kappadath S. Quantification of in Vivo tumor uptake in clinical molecular breast imaging (MBI) examinations. Med Phys 44(6):3263, 2017.
129. Kappadath SC, Lopez B, Adrada B, Hess K, Rauch G. Prediction of breast tumor response to neoadjuvant chemotherapy through quantitative 99mTc sestamibi Molecular Breast Imaging (MBI). Eur J Nucl Med Mol Imaging 44(Suppl 2):5660, 2017.
130. Lopez B, Rauch GM, Adrada BE, Bache S, Hess K, Kappadath SC. Quantifying Tc-99msestamibi uptake in breast tumors using molecular breast imaging. Med Phys 44(6):3263, 2017.
131. Rauch GM, Adrada BE, Kappadath C, Ma J, Muller F, Moulder S, Yang W. In vivo molecular breast imaging with Tc 99m sestamibi for the prediction of multidrug resistance in triple negative breast cancers, 2017.
132. Lane DL, Santiago L, Candelaria RP, Scoggins ME, Rauch GM, Adrada BE, Huang ML, Geiser WR, Hess K. Synthesized mammography (SM) versus full-field digital mammography (FFDM): a comparison of lesion detection by radiologists. Proceedings of the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2016.
133. Swanick CW, Castle KO, Vedam S, Munsell MF, Turner LM, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Comparison of CT- and MRI-based clinical target volume contours at the time of brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 93(3):E282, 2016. e-Pub 2016.
134. Rauch GM, Tamm EP, Bhosale PR, Devine C, Rao-Korivi B, Szklaruk J. Dual energy CT for evaluation of vascular anatomy in patients with hepatobiliary and pancreatic cancer, 2016.
135. Ho J, Allen P, Bhosale P, Rauch G, Fuller C, Mohamed A, Fruimovitz M, Jhingran A, Eifel P, Klopp A. Functional imaging predictors of outcome in cervical cancer following chemoradiation. Brachytherapy 15(Supplement 1):S106, 2016.
136. Bache S, Adrada B, Jessop A, Rauch G, Kappadath S. Quantification of tumor uptake with molecular breast imaging (MBI). J Nucl Med 57(Suppl):535, 2016.
137. Santiago L, Candelaria RP, Arribas EM, Huang ML, Scoggins ME, Adrada BE, Rauch GM, Thames D, Whitman GJ. Noncalcified ductal carcinoma in situ: the danger that lies beneath. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
138. Rauch GM, Adrada BE, Huang ML, Candelaria RP, Arribas EM, Yang WT, Cox K, Santiago L, Kappadath S. Molecular breast imaging: an adjunct diagnostic modality for breast cancer evaluation. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
139. Candelaria RP, Huang ML, Adrada BE, Arribas EM, Scoggins ME, Yang WT, Schopp J, Dryden M, Le-Petross HC, Moseley T, Whitman G, Rauch GM, Santiago L. Comparing the performance of full-field digital mammography (FFDM), digital breast tomosynthesis (DBT) and whole breast ultrasound (WBUS) in the initial staging evaluation of breast cancer: interim results of a prospective study. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
140. Huang ML, Speer ME, Dogan BE, Rauch GM, Candelaria RP, Yang WT, Hess K, Adrada BE. Following imaging-concordant benign MRI-guided vacuum-assisted breast biopsy: is MRI follow up needed?. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
141. Adrada BE, Huang ML, Candelaria RP, Santiago L, Rauch GM, Arribas EM, Dawson D, Albarracin C, Moseley T, Whitman G. Intraoperative specimen radiography - going beyond the block. Proceedings of the 101st Scientific Assembly and Annual Meeting, Radiological Society of North America, 2015.
142. Shin K, Adrada BE, Rauch GM, Benveniste AP, Yang WT. American Joint Committee on Cancer (AJCC) Breast cancer staging - Multimodality regional nodal basin imaging, 2015.
143. Ho J, Allen P, Bhosale P, Rauch G, Fuller C, Mohamed A, Fruimovitz M, Jhingran A, Eifel P, Klopp A. Functional imaging predictors of outcome in cervical cancer following chemoradiation. Int J Radiat Oncol Biol Phys 93(3):E289, 2015.
144. Rauch GM, Tamm E, Bhosale P Devine C, Rao-Korivi B, Szklaruk J. Evaluation of vascular anatomy in patients with hepatobiliary and pancreatic cancer by dual energy CT imaging. Society of Computed Body Tomography & Magnetic Resonance, 2015.
145. Bache S, Adrada B, Jessop A, Rauch G, Kappadath S. Scatter and attenuation correction approaches for quantitative molecular breast imaging. J Nucl Med 56(3):45, 2015.
146. Arribas EM, Huang ML, Adrada BE, Rauch GM, Gilcrease M, Yang WT. Giant breast masses: differential diagnosis with multimodality and histopathology correlation. Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
147. Huang ML, Monetto FP, Arribas EM, Rauch GM, Krishnamurthy S, Adrada BE. Manifestation of hematologic diseases in the breast: multimodality review with patholofic correlation. Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
148. Huang ML, Monetto FP, Arribas EM, Rauch GM, Krishnamurthy S, Adrada BE. Primary lymphoma of the breast: multimodality features with pathologic correlation and management review. Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
149. Rauch GM, Bhosale PR, Tamm EP, Devine CE, Rao B, Szklaruk J. Hepatobiliary and pancreatic vascular anatomy in the era of dual energy CT (DECT). Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
150. Rauch GM, Hobbs B, Kuerer HM, Scoggins ME, Benveniste AP, Yang WT, Park YM, Adrada BE, Fox P, Krishnamurthy S. Mammographic features of microcalcifications and survival in patients with pure ductal carcinoma in situ of the breast: population based retrospective cohort study. Proceedings of the 100th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2014.
151. Swanick CW, Castle KO, Cunningham MG, Vedam S, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Impact of normal tissue motion on dose to critical structures during intracavitary brachytherapy. Radiat Oncol Biol Phys 90(1):S482, 2014.
152. Swanick CW, Castle KO, Rachner LA, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Optimizing packing contrast for MRI-based intracavitary brachytherapy treatment planning. Brachytheraphy 13(Supplement 1):S57-S58, 2014.
153. Adrada BE, Rauch GM, Adeyefa MM, Huo L, Stephens TW, Yang WT. Management of fat necrosis of the breast according to imaging features. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
154. Bathala T, Rauch GM, Bass M, Borst D, Hobbs B, Bedi DG. Diagnostic performance of conventional ultrasonography combined with US strain elastography for differentiation between benign and malignant subcutaneous soft tissue mass lesions. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
155. Rauch GM, Hobbs B, Kuerer H, Scoggins M, Lari S, Yang W, Benveniste AP, Park YM, Adrada B, Fox P, Krishnamurthy S. Microcalcifications in 1,658 patients with pure ductal carcinoma in situ of the breast: imaging findings with clinical, histopathologic and biologic correlation. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
156. Rauch GM, Marcal LP, Castle KO, Klopp A. MRI in intracavitary brachytherapy of the cervical cancer: what radiologists need to know. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
157. Marcal LP, Rauch GM, Kaur H, Foo WC, Loyer EM. Pre-operative imaging of hilar cholangiocarcinoma: what the surgeon wants to know. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
158. Scoggins M, Rauch GM, Fox P, Benvensite AP, Kuerer H, Yang W, Park YM, Lari S, Krishnamurthy S. Sonographic findings in 691 pure ductal carcinoma in situ lesions with histopathologic and biologic correlation. Proceedings of the 99th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2013.
159. Rauch GM, Ernst R, Marcal LP, You NY, Chang GJ, Rodriguez-Bigas M, Choi H, Kaur H. High-resolution MRI in the presurgical evaluation of low rectal tumors. American Roentgen Ray Society Annual Meeting, 2013.
160. Rauch GM, Kuerer H, Scoggins M, Benveniste AP, Fox P, Yang W, Park YM, Lari S, Hobbs B, Krishnamurthy S. Biologic subtype and imaging correlates of 1,187 patients with pure ductal carcinoma in situ of the breast. Proceedings of the 98th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2012.
161. Rauch GM, Kuerer HM, Benveniste AP, Scoggins ME, Fox PS, Park YM, Lari SA, Hobbs BP, Krishnamurthy S, Yang W. Ductal carcinoma in situ: correlation of estrogen hormone receptor expression on clinicopathological and imaging features. Proceedings of the 98th Scientific Assembly and Annual Meeting, Radiological Society of North America, 2012.
162. Rauch GM, Marcal LP, Ernst RD, Klopp AH, Boonsirikamchai P, Westin SN, Choi H, Kaur H. High resolution multiplanar MR imaging for pretreatment staging of cervical and endometrial cancer. Society of Computed Body Tomography & Magnetic Resonance, 2012.
163. Rauch GM, Dogan BE, Liu P, Huo L, Yang WT. Underestimation of high-risk lesions at 9-guage MRI-guided vacuum assisted breast biopsies. Proceedings of the Annual Meeting of the American Roentgen Ray Society, 2012.
164. Ernst R, Kaur HN, Rauch GM, Chang G, You Y, Skibber J, Rodriguez-Bigas M, Raval B, Marcal LP, Choi H. Key findings in rectal cancer with emphasis on 3T MRI. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
165. Marcal LP, Rauch GM, Kaur H, Ernst R, Choi H. High-resolution MR imaging of cervical cancer. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
166. Jensen CT, Rauch GM, You YN, Chang GJ, Choi H, Ernst RD, Kaur H. Mucinous adenocarcinoma of the rectum: disease patterns and pitfalls. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
167. Rauch GM, Ernst R, Marcal LP, Boonsirikamchai P, Klopp A, Choi H, Kaur H. Optimization of high-resolution MRI technique for pretreatment staging of cervical and endometrial cancer. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
168. Rauch GM, Ernst R, Marcal LP, You NY, Chang GJ, Skibber J, Rodriguez-Bigas M, Choi H, Kaur H. Role of the high-resolution MRI in the presurgical evaluation of low rectal tumors. Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
169. Jensen CT, Ernst R, Chang C, You NY, Hou P, Choi H, Rauch GM, Kaur H. Preoperative MRI staging of rectal cancer. Proceedings of the American Roentgen Ray Society Annual Meeting, 2011.
170. Faria SC, Marcal LP, Bhosale PR, Sagebiel T, Rauch GM, Szklaruk J, Nasseri F, Ginsberg L, Eftekhari F. Large common and uncommon retroperitoneal masses: a radiological approach to the correct diagnosis. Proceedings of the 96th Annual Meeting of the Radiological Society of North America, 2010.
171. Kaur H, Ernst R, Rauch GM, Jensen C, You NY, Hou P, Choi H. Preoperative staging of primary rectal cancer: role of thin section multiplanar 2D T2 imaging, 3D T2 and diffusion-weighted imaging. Proceedings of the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2010.
172. Rauch GM, Dogan B, Liu P, Yang W. Outcome analysis of 9-gauge MRI-guided vacuum assisted breast biopsy. Proceedings of the 95th Annual Meeting of the Radiological Society of North America, 2009.
173. Rauch GM, Vikram R, Vining D, Iyer R. Extracolonic findings on CT colonography in cancer patients. Proceedings of the Annual Meeting of the American Roentgen Ray Society, 2009.
174. Meyer JS, Rauch GM. Before thrombolytic therapy for acute stroke xenon inhalation contrast CT CBF imaging is recommended. Stroke: Abstracts from the 4th World Stroke Congress 31(11):2838, 2000.
175. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors for mild cognitive decline and dementia of the vascular and Alzheimer's types. Stroke A Journal of the American Heart Association 31:319, 2000.
176. Meyer JS, Thornby K, Crawford K, Rauch GM, Li Y. Migraine and cluster headaches cause temporary cognitive impairments. Cephalalgia 20:381-382, 2000.
177. Meyer JS, Thornby J, Crawford K, Rauch GM. Reversible cognitive decline accompanies migraine and cluster headaches. Ann Neurol:41, 2000.
178. Meyer JS, Rauch GM. Cerebral vasodilator responses to Diamox in cortical versus subcortical vascular dementia. Proceedings of the 21st Salzburg Conference, 2000.
179. Meyer JS, Margishvili GM, Haque A, Rauch RA, Terayama Y, Konno S. Risk factors for cerebral degeneration and dementia. Proceedings of the 10th Salzburg Conference:39, 1999.
180. Rauch GM, Meyer JS, Haque A, Rauch RA. Aging: risk factors for cognitive decline and dementia. J Cereb Blood Flow Metab 19(Suppl 1):S15, 1999.
181. Meyer JS, Rauch GM, Mortel KF, Rauch RA, Akiyama H, Konno S, Terayama Y. Risk factors for vascular dementia. J Stroke Cerebrovasc Dis 2(Suppl 1):37-38, 1999.
182. Meyer JS, Terayama Y, Konno S, Akiyama H, Margishvili GM, Mortel KF. Cardiovascular and related risk factors for vascular dementia. Eur Neurol 5(Suppl 1):S4, 1998.
183. Fife C, Meyer JS, Margishvili GM. The use of hyperbaric oxygen in the treatment of headache. Proceedings of the Interdisciplinary Symposium on Hyperbaric Oxygen Therapy (iSHOT 1998):41-53, 1998.
184. Meyer JS, Margishvili GM. Hypertension as a risk factor for vascular dementia. Proceedings of the International Psychogeriatric Association:70, 1998.
185. Konno S, Meyer JS, Margishvili GM, Haque A. Transformed migraine as a cause of chronic daily headache. Proceedings of the XII Migraine Trust International Symposium:14-15, 1998.
186. Meyer JS, Akiyama H, Mortel KF, Konno S, Margishvili GM. Risk factors in cerebral atrophy during human aging. Neurology A(48):206, 1997.
187. Akiyama H, Meyer JS, Mortel KF, Terayama Y, Konno S, Margishvili GM,. Risk factors for cerebral atrophy and cognitive declines. J Cereb Blood Flow Metab 17(Suppl 1):S625, 1997.
188. Meyer JS, Terayama Y, Akiyama H, Konno S, Mortel KF, Margishvili GM, Will PM. Cerebrovascular disease alters the course and symptoms of migraine. J Neurol Sci 150:S35, 1997.
189. Meyer JS, Akiyama H, Terayama Y, Mortel KF, Konno S, Margishvili GM. Cerebral degenerative changes during aging with cognitive declines. J Stroke Cerebrovasc Dis 6:439, 1997.
190. Meyer JS, Terayama Y, Akiyama H, Konno S, Mortel KF, Margishvili GM, Wills PM. Development of cerebrovascular disease alters the course and symptoms of migraine. Headache 37(5):323, 1997.
191. Meyer JS, Terayama Y, Konno S, Akiyama H, Mortel KF, Margishvili GM. Aging and risk factors for cognitive declines. Ann Neurol 42(3):399, 1997.
192. Meyer JS, Terayama Y, Konno S, Akiyama H, Mortel KF, Margishvili GM. Aging: risk factors for cerebral CT changes and risk of dementia. Proceedings of 8th Congress of the International Psychogeriatric Association:81, 1997.
193. Meyer JS, Akiyama H, Terayama Y, Konno S, Mortel KF, Margishvili GM. Classification of the vascular dementias validated. J Stroke Cerebrovasc Dis(6):452, 1997.
194. Margishvili GM, Madorski SV, Duasheva AA, Churilov MV, Lasarev VA. Evaluation of giant basilar aneurysms with transcranial color-coded duplex sonography. Stroke A Journal of the American Heart Association 27(S):794, 1996.
195. Margishvili GM, Amcheslavski VG. TCD evaluation of cerebral blood flow in patients with meningiomas involving the cavernous sinus. Stroke A Journal of the American Heart Association 27(S):795, 1996.
196. Madorski SV, Margishvili GM, Dausheva AA, Churilov MV, Lasarev VA, Fokin MS. Giant basilar aneurysms: use of transcranial color-coded duplex sonography for non-invasive diagnosis and long term follow-up. Proceedings of All-Russian Conference on Modern Methods of Ultrasound Diagnosis:67, 1996.
197. Margishvili GM, Amcheslavski VG, Shimanski VN. Evaluation of blood flow in cerebral basal arteries in patients with craniobasal meningiomas: TCD and AG investigation. Proceedings of All-Russian Conference on Modern Methods of Ultrasound Diagnosis:70, 1996.
198. Margishvili GM, Amcheslavski VG, Madorski SV, Parfenov AL, Toma GI, Fokin MS, Gaitur EI. Non-invasive monitoring in ICU patients after head injury and subarachnoid hemorrhage. Proceedings of 16th Annual Symposium on Computing in Anesthesia and Intensive Care:54, 1996.
199. Amcheslavski VG, Bragina NN, Parfenov AL, Margishvili GM, Toma GI, Gaitur EI, Madorski SV, Shaginian GG. Modern methods of intensive care of head injury patients. Proceedings of Conference on Actual Problems of Neurosurgery:18-19, 1996.
200. Amcheslavski VG, Margishvili GM, Parfenov AL, Toma GI, Gaitur EI. Monitoring of severe head injury patients. Proceedings of Conference on Actual Problems of Neurosurgery:25-26, 1996.
201. Gaitur EI, Potapov AA, Amcheslavski VG, Lichterman LB, Kravchuk AD, Parfenov AL, Margishvili GM, Toma GI, Emalianov VK, Leonov VG, Fazulin BR. Significance of arterial hypotonia and hypoxia in head injury patients. Proceedings of Conference on Actual Problems of Neurosurgery:24-25, 1996.
202. Margishvili GM, Amcheslavski VG, Parfenov AL, Fokin MS, Toma GI, Gaitur EI, Dausheva AA. Complex cerebral monitoring in ICU patients after severe head injury and subarachnoid hemorrhage. Proceedings of All-Russian Congress of Anesthesiology and Reanimathology 1:20, 1996.
203. Amcheslavski VG, Bragina NN, Parfenov AL, Margishvili GM, Toma GI, Gaitur EI, Madorski SV, Shaginian GG. Intensive care for patients in acute period of severe head injury. Proceedings of All-Russian Congress of Anesthesiology and Reanimathology 2:7, 1996.
204. Margishvili GM, Amcheslavski VG, Shimanski VN. TCD Evaluation of cerebral blood flow in patients with tumors involving the cavernous sinus before and after surgery. Cerebrovasc Dis:8, 1996.
205. Amcheslavski VG, Margishvili GM, Madorski SV, Toma GI, Voronina IA. Non-invasive cerebral monitoring in ICU. Proceedings of 4th International Symposium of Central Nervous System Monitoring, 1996.
206. Madorski SV, Amcheslavski VG, Voronina IA, Margishvili GM. Neurophysiological monitoring after hypophysis and hypothalamus tumors excision. Proceedings of 4th International symposium Central Nervous System Monitoring, 1996.
207. Amcheslavski VG, Margishvili GM, Toma GI, Madorski SV, Parfenov AL, Shaginian GG, Gaitur EI. Non-invasive multipurpose cerebral monitoring of head injured patients in ICU. Proceedings of International Conference on Recent Advances in Neurotraumatology:285, 1996.
208. Parfenov AL, Demchuk ML, Amcheslavski VG, Margishvili GM, Shaginian GG, Gaitur EI. Treatment of endogenic intoxication with the use of sodium hypochlorite in resuscitation patients. Proceedings of International Symposium on Reanimathology on the Eve of the 21st Century:153-154, 1996.
209. Gaitur EI, Potapov AA, Amcheslavski VG, Margishvili GM, Toma GI, Parfenov AL, Emelianov VK, Mukhametdzhavnov HM, Leonov VG, Fazulin BR. Arterial hypotony influence on course and outcomes of severe head injury. Proceedings of International Symposium on Reanimathology on the Eve of the 21st Century:126-128, 1996.
210. Gaitur EI, Potapov AA, Amcheslavski VG, Margishvili GM, Toma GI, Parfenov AL, Emelianov VK, Mukhametdzhavnov HM, Leonov VG, Fazulin BR. Arterial hypoxemia effect on outcomes in severe isolated and combined cranio-cerebral trauma. Proceedings of International Symposium on Reanimathology on the Eve of the 21st Century:125-126, 1996.
211. Amcheslavski VG, Madorski SV, Parfenov AL, Margishvili GM, Toma GI, Savin IA, Fokin MS. Peculiarities of critical states in neurosurgical patients in the postoperative period. Proceedings of International Symposium on Reanimathology on the Eve of the 21st Century:111-112, 1996.
212. Amcheslavski VG, Margishvili GM, Toma GI, Demchuk ML, Dzubanova NA. Nimotop-S in intensive care of critical condition of neurosurgical patients. Proceedings of 3rd Russian Congress Human and Medicine:251, 1996.
213. Amcheslavski VG, Toma GI, Parfenov AL, Margishvili GM, Fokin MS, Gaitur EI. Diagnosis of cerebral hypoxia using near infrared spectroscopy. Proceedings of All-Russian Medical Research Conference:109-110, 1996.
214. Sokolova AA, Margishvili GM, Kopahkov VA, Yundin VI. Use of somatosensory evoked potentials in spinal neurosurgery. J Neurotrauma 12(S):447, 1995.
215. Boldyreva GN, Margishvili GM, Bragina NN. Space occupying lesion influence on limbic system: clinical and neurophysiological analysis. Proceedings of the International Symposium on Structural and Functional Organization of the Brain:25, 1995.
216. Grindle OM, Koptelov YM, Masherov YL, Voronina IA, Margishvili GM. BRAINLOC method for localization of EEG pathological activity zones in patients with space occupying lesions in the brain. Proceedings of the 1st All-Russian Congress in Neurosurgery:191, 1995.
217. Margishvili GM, Bragina NN, Boldyreva GN. Clinical features of mediobasal temporal meningiomas. Proceedings of the 1st All-Russian Congress of Neurosurgery:204, 1995.
218. Amcheslavski VG, Margishvili GM, Dzubanova NA, Madorski SV, Demchuk ML. Nimotop in neurosurgical ICU practice. Proceedings of the 1st All-Russian Congress of Neurosurgery:10, 1995.
219. Boldyreva GN, Manelis NG, Margishvili GM Masherov EL. Influence of limbic system lesions on brain electrical activity. Proceedings of the Symposium on the Neurophysiological Basis for Mental Function Development:11, 1995.
220. Sokolova AA, Margishvili GM, Kopahkov VA, Yundin VI. Value of somatosensory evoked potentials in spinal neurosurgery. Proceedings of the 10th European Congress of Neurosurgery:188, 1995.
221. Bragina NN, Margishvili GM, Amcheslavsi VG, Barkalaya D. The early postoperative period in patients with craniobasal tumors involving the cavernous sinus. Proceedings of the International Skull Base Symposium:36, 1994.
222. Amcheslavsi VG, Bragina NN, Dzubanova N, Barkalaya D, Margishvili GM. The postoperative period in patients with tumors of the skull base region. Proceedings of the International Skull Base Symposium:36, 1994.
223. Margishvili GM, Livshits AV. Somatosensory evoked potentials dynamic in patients after spinal cord tumor surgery. Proceedings of the 1st Congress of Young Clinician Scientists 1:205-206, 1991.
224. Margishvili GM, Duchidze SH. Gnostic disturbances in patients with right hemispheric lesions. Proceedings of the 51st All-Union Students' Scientific Conference:181, 1988.
225. Margishvili GM, Mudchiri T. Leukocytes functional activity in patients with diabetic gangrene. Proceedings of the 50th All-Union Students' Scientific Conference:87, 1987.
226. Margishvili GM, Besselia N. Leukocytes functional activity in pulmonary inflammatory processes. Proceedings of the 49th All-Union Students' Scientific Conference:121, 1986.
227. Margishvili GM. Reaction of different caliber arteries on oliogocytemic hypervolemia. Proceedings of the 48th All-Union Students' Scientific Conference:48, 1985.
228. Johnson HM, Smith B, Rauch GM, Krishnamurthy S, Yang W, Valero V, Lucci A, Boughey JC, White RL, Diego E, Shaitelman SF, Mitchell MP, Kuerer HM. Multicenter clinical trial for omission of breast surgery in invasive cancer following neoadjuvant systemic therapy: Longitudinal patient reported outcomes and decisional comfort planned analyses. Society of Surgical Oncology.
229. Wu C, Stowers C, Jarrett AM, Zhou Z, Ma J, Rauch GM, Yankeelov TE. MRI-based digital twins forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. ISMRM.
230. Zandbergen CAW, Han S, Nevozhay D, Meyer JM, Rauch GM, Cook J, Sokolov K, Bouchard RR. Noninvasive quantitation of EGFR-targeted PAtrace with photoacoustic imaging to assess treatment response in a preclinical model of breast cancer. International Ultrasonics Symposium.
231. Johnson HM, Smith BD, Rauch GM, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Moseley TW, Leung JWT, Huang M, Candelaria RP, Adrada BE, Arribas E, la Parra RFD, Hung KK, Bedrosian I, Teshome M, Sun SX, Hwang RF, Miggins MV, Piotrowski M, Refinetti AP, Ehlers RA, Colen JS, Loveland-Jones C, Lesnikowski BA, Samiian L, Chong C, Shaitelman SF, Mitchell MP, Kuerer HM. Eliminating breast surgery for invasive cancer following neoadjuvant systemic therapy (NST): Prospective multicenter clinical trial first planned feasibility report. Western Surgical Association.
232. Jacobsen MC, Beriwal S, Dyer BA, Klopp AH, Lee SI, McGinnis GJ, Robbins JB, Rauch GM, Sadowski EA, Simiele SJ, Stafford RJ, Taunk NK, Yashar CM, Venkatesan AM. Image-guided cervical cancer brachytherapy: Summary of consensus recommendations from the Society for Abdominal Radiology and American Brachytherapy Society. American Brachytherapy Society's Annual Meeting.
233. Wu C, Stowers CE, Kumar S, Tamir JI, Patel RJS, Mohammed RMM, Rauch GM, Yankeelov TE. MRI-based digital twins to forecast treatment response in breast cancer patients. NCI CIRP Annual Virtual Meeting 2023.
234. Lopez BP, Rauch GM, Kappadath SC. Absolute 99mTc-Sestamibi breast uptake in HER2-, HER2+, and TNBC patients undergoing neoadjuvant chemotherapy. American Association of Physicists in Medicine.
235. Lucci A, Addanki S, Kalashnikoca E, Renner D, Kuerer H, Meas S, Sarli V, White J, Rauch G, Tripathy D, Arun B, Yam C, Rodriguez A, Liu MC, Moulder S. Monitoring response to neoadjuvant chemotherapy in TNBC using circulating tumor DNA. European Society for Medical Oncology.
236. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Zu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathu D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. 45th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
237. Stowers CE, Wu C, Kumar S, Lima EABF, Xu Z, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Developing MRI-based digital-twins via mathematical modeling and deep learning to predict the response of triple-negative breast cancer to neoadjuvant therapy. 2023 AACR Annual Meeting.
238. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross H, Leung JWL, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White JB, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Early Prediction of Response to Neoadjuvant Systemic Therapy of Triple Negative Breast Cancer using Radiomics on DCE-MRI. ISMRM & ISMRT 2023 Annual Meeting.
239. Wu C, Stowers CE, Xu Z, Lima EABF, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE.. Quantification of tumor-associated vasculature as an imaging biomarker for monitoring the response of triple-negative breast cancer to neoadjuvant chemotherapy. AACR Annual Meeting 2023.
240. Xu Z, Pashapoor S, Panthi B, Son JB, Hwang KP, Adrada BE, Candelaria RP, Guirguis MS, Patel MM, Le-Petross H, Leung J, Scoggins ME, Whitman G, Mohamed R, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Chen H, Sun J, Wei P, Thompson A, Korkut A, Huo L, Hunt K, Moulder S, Litton J, Valero V, Tripathy D, Yang W, Yam C, Rauch GM, Ma J. Tumor segmentation with nnU-Net on dynamic contrast enhanced MR images of triple negative breast cancer. ISMRM & ISMRT 2023 Annual Meeting.
241. Lopez B, Rauch GM. Absolute breast 99mTc-sestami quantification with molecular breast imaging in patients undergoing neoadjuvant chemotherapy. SNMMI Annual Meeting.
242. Wu C, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE, Lima EABF. Optimization of a longitudinal imaging protocol to monitor the response of breast cancer to neoadjuvant therapy via Bayesian-based data assimilation. Society of Mathematical Biology Annual Meeting.
243. Rauch GM, Guirguis MS, Patel M, Candelaria RP, Mohamed RM, Yang WT, Moseley TW, Le-Petross H, Leung JW, Whitman GJ, Lane DL, Scoggins ME, Perez F, Sun J, Moge M, White J, Xu Z, Wei P, Son JB, Hwang K, Panthi B, Korkut A, Huo L, Hung KK, Clayborn A, Litton J, Valero J, Valero V, Tripathy D, Yam C, Ma J, Adrada BE. DCE-MRI volumetric changes predict response to neoadjuvant immunotherapy in triple negative breast cancer patients. Radiological Society of North America.
244. Hruska C, Hunt K, Miller P, Ellis R, Shermis R, Rauch M, Conners A, Zingula S, Whaley D, Spilde JG, Mandava S, Semaan D, Siegal E, Redfern R, Adrada B, Ellingson L, Larson N, Mehta R, Rhodes D. Molecular breast imaging for women with dense breasts: results update from the density matters trial. Radiological Society of North America.
245. Kuerer HM, Rauch GM, Krishnamurthy S, Diego EJ, Yang WT, Shen Y, Lin H, Lucci A, Ramirez DL, Moseley TW, Mouabbi JA, Boughey JC, Shaitelman SF, White RL, Hunt KH, Mitchell MP, Teshome MT, Johnson HM, Smith BD, Valero V. Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial. ESMO.
246. Christenson C, Wu C, Hormuth II DA, Pash G, Stowers C, LaMonica M, Wilcox K, Ma J, Rauch GM, Yankeelov TE. Introducing mechanical stress into a reduced order model for breast cancer response to chemotherapy. BMES Annual Meeting.
247. Wu C, Lima EABF, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Optimization of longitudinal imaging protocol to monitor triple-negative breast cancer (TNBC) response to neoadjuvant chemotherapy via Bayesian-based data assimilation. Society for Mathematical Biology Annual Meeting.
248. Stowers CE, Wu C, Kumar S, Xu Z, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Integrating mechanism-based and data-driven modeling to predict the response of triple negative breast cancer to therapy. Mathematical Oncology.
249. Patel RJS, Wu Ch, Stowers CE, Mohammed RMM, Kasprick TS, Rauch GM, Yankeelov TE. Predicting the response of I-SPY 2 breast cancer patients to treatment using a mechanism-based model and quantitative MRI data. Mathematical Oncology.

Book Chapters

1. Guo C, Bhosale PR, Rauch GM, Matamoros A, Menias C, Schmeler KM, Iyer RB, Venkatesan AM. Tumors of the uterine corpus. In: Oncologic Imaging: A Multidisciplinary Approach. 2nd. Elsevier: Philadelphia, 414-437, 2022.
2. Rauch GM, Guirguis MS, Adrada BE. After breast conservation therapy. In: CORE Requisites: Breast Imaging. 4th. Elsevier: Philadelphia, 212-232, 2022.
3. Haque A, Meyer JS, Rauch GM. Epidemiology of vascular dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 1-8, 2001.
4. Meyer JS, Rauch GM. Cardiovascular risk factors contributing to cerebral degenerative changes, cognitive decline, and dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 19-39, 2001.
5. Rauch GM, Meyer JS. Clinical features of patients with vascular dementia versus Alzheimer's disease. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
6. Haque A, Meyer JS, Rauch GM. Neuropsychological assessments for cognitive decline. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
7. Loeb C, Meyer JS, Rauch GM. Criteria for diagnosis of vascular dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
8. Meyer JS, Rauch GM. Classification of subtypes of vascular dementia including subcortical versus cortical dementias. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
9. Meyer JS, Rauch GM, Rauch RA. Neuroimaging in vascular dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
10. Meyer JS, Rauch GM. Prevention and treatment of vascular dementia. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
11. Rauch GM, Meyer JS. Estrogen therapy for prevention of dementia in post-menopausal women. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
12. Meyer JS, Rauch GM. Factors influencing long-term survival among patients with vascular dementia versus Alzheimer's disease. In: Vascular Dementia. Futura Publishing Company: Armonk NY, 2001.
13. Meyer JS, Rauch GM, Haque A, Rauch RA. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. In: Vascular Factors in Alzheimer's Disease. Cambridge: UK, 1, 1999.
14. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors contributing to dementias of vascular and Alzheimer types. In: Proceedings of the 1st International Congress on Vascular Dementia: Geneva Switzerland, 67-70, 1999.
15. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors of cerebral hypoperfusion, cognitive decline, and dementia. In: Hemodynamics and cerebral perfusion: new evidence in the pathology of Alzheimer's Disease: Boston, 1999.

Books (edited and written)

1. Meyer JS, Rauch GM, Lechner H, Loeb C, Toole JF. Vascular dementia. Ed(s) Meyer JS, Rauch GM, Lechner H, Loeb C, Toole JF. Futura Publishing Company: Armonk, NY, 2001.

Letters to the Editor

1. Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V. Optimal selection of breast cancer patients for elimination of surgery following neoadjuvant systemic therapy. Ann Surg 268: e61-e62, 2018.
2. Kuerer HM, Krishnamurthy S, Rauch GM, Smith B, Valero V, Yang W. Response: Vacuum-assisted biopsy to diagnose a pathological complete response in breast cancer patients after neoadjuvant systemic therapy. Ann Surg, 2017.